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CHAPTER 1 
INTRODUCTION 
 
1.1 Dengue Fever (DF) and Dengue Haemorrhagic Fever (DHF) 
1.1.1 Symptoms and prevalence 
 
Dengue is a mosquito-borne viral infectious disease that has become a major 
public health concern in the recent years.  Human infected by this disease will exhibit 
fever of 3 to 5 days, intense headache, myalgia, anthralgic retro-orbital pain, anorexia, 
GI disturbances, rash and leucopenia as symptoms.  
 
Dengue is usually found in tropical and sub-tropical regions around the world, 
mainly in urban and semi-urban areas.In the recent years, dengue become as a serious 
disease that is endemic in over 100 countries(Figure 1.1),with more than 2.5 billion 
people at risk for epidemic transmission (Gubler, 1996).  About 100 million cases of 
Dengue Fever (DF) and 500 000 cases of Dengue Haemorrhagic Fever (DHF) have 
been reported globally with this figure is still rising (http://www.searo.who.int/en/ 
Section10/Section332_1103.htm, 14 August 2006). 
 
Dengue Haemorrhagic Fever (DHF) epidemic was first reported in 1953 in the 
Philippines. This disease has greatly expanded to most Asian countries and has become 
the top ten leading causes of hospitalisation and death among children (WHO, 1997). 
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In Malaysia, a recent report revealed 38 deaths in the first 10 weeks of 2010 
amongst 10,462 cases of dengue fever.  In comparison, in 2009 statistics showed 41,486 
dengue cases with 88 deaths reported.  The death cases in the first 10 weeks of 2010 
already comprised 43% of the death cases in 2009. (http://www.moh.gov.my/MohPortal 
/newsFull.jsp?action=load&id=432, 14 March 2010).  40% of the world's populations 
are now at risk from dengue without effective treatment, vaccine or drug (Kautner et al., 
1997; Monath, 1994).  
 
 
Figure 1.1: World distribution of Dengue in year 2008 (source: http://www.cdc.gov/ 
dengue/resources/Dengue&DHF%20Information%20for%20Health%20Care%20Practit
ioners_2009.pdf, 15 May 2010) 
 
 
1.1.2 Diagnosis and treatment 
 
Thrombocytopenia and haemoconcentration are the constant indication for a 
patient infected with dengue virus.  A person infected by the dengue virus would 
typically exhibit a drop of platelet count to below 100 000 per mm3 between the 3rd and 
8th day of the fever.  A rise in haematocrit level indicating plasma leakage is always 
observed in the blood stream of DHF patients.  Other common observations such as 
hypoproteinaemia caused by the loss of albumin, hyponatraemia, and increased level of 
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serum aspartate aminotransferase are also commonly observed. Pleural effusion on the 
right side of chest is also visible under X-ray in dengue patients. (WHO, 1997) 
 
Patients with dengue infection could only be treated at the early stage of the 
infection by relieving the symptoms to prevent complications and death. Appropriate, 
intensive and supportive therapy by maintaining the circulating fluid volume of the 
patient is given to reduce the mortality to less than 1%.  Aspirin and ibuprofen are 
avoided due to its ability to increase bleeding tendency and stomach pain. Painkillers 
such as paracetamol are often prescribed on medical advice and patients will be 
hospitalised immediately after being diagnosed with DHF disease. (http://www.searo. 
who.int/EN/Section10/Section332/Section1631.htm, 4 August 2006) 
 
1.2 Dengue Virus, the Genome and Lifecycles 
1.2.1 Transmission 
 
Dengue fever and dengue haemorrhagic fever are caused by dengue virus of the 
flavivirus family.  There are 4 serotypes of dengue viruses; denoted as DEN1, DEN2 
DEN3 and DEN4.  The DEN2 serotype is the most prevalent amongst the four 
serotypes.  The recovery from the infection by one serotype will provide lifelong 
immunity against that particular serotype, but only partial and transient protection 
against subsequent infections by the other three serotypes. There have been clinical 
evidences showing that sequential infection will increase the risk of more serious 
disease resulting in DHF (http://www.searo.who.int/en/Section10/Section332_1103.htm 
, 14 August 2006).  
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The main dengue vector is the female mosquito of the species Aedes aegypti and 
Aedes albopictus.  An infected mosquito can remain infected for life. The virus is 
transmitted to a person when the mosquito feeds on a dengue patient during the first to 
fifth days of illness.  Following the virus incubation period for 8-10 days in the vector, 
the virus can then be transmitted by these Aedes mosquitoes to susceptible individuals 
through blood feeding (http://www.who.int/mediacentre/factsheets/fs117/en/, 13 March 
2009).    
 
1.2.2 Polyprotein processing  
 
Dengue viruses are single-stranded, positive-sense RNA that has approximately 
10,723 nucleotides.   The genomic RNA has a single open reading frame that encodes a 
polyprotein of 3,391 amino acids.  These amino acids are processed into 3 structural 
proteins (core protein, C; membrane-associated protein, prM; and envelope protein, E) 
and seven non-structural proteins; NS1 to NS5 that are further assembled into the virion.  
The virion is approximately 50 nm in diameter.  These proteins are expressed in the 
infected cells (Irie et al., 1989), as depicted in Figure 1.2.  
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Figure 1.2: Structural and non-structural polyproteinassembly of DEN2 virus.(a) 
Schematic representation of dengue virus structure and morphology (b) Arrangement of 
viral proteins in the single and positive stranded dengue RNA genome-encoded 
precursor polyprotein with their respective cleaving enzyme 
 
  
The envelope protein, which is a part of structural protein, is responsible for 
neutralization, fusion and interactions with virus receptors on the target cell (Klasse et 
al., 1998).  Through receptor mediated endocytosis or direct fusion, target cells can be 
penetrated by the virus.  Jahn and co-workers (Jahn et al., 2003) reported that the fusion 
process of the virus envelope protein could be controlled by specific fusion proteins 
which are complexed with lipids and other proteins at the fusion site.   “Fusion peptide”, 
a term given to the special segment of a polypeptide chain of fusion proteins, is exposed 
and inserted into the target cell during the fusion process.  There are at least two 
different classes of structural viral fusion proteins, termed Class I and Class II.   
 
Dengue virus envelope polyprotein, like other flaviviruses and alphaviruses, is 
classified as Class II fusion protein (Rey et al., 1995).  The fusion protein appears as an 
  prM  E   NS1  NS3
3 
 NS5  2
a 
 2b  4
a 
 4b C 
 
: NS2B/NS3 serine protease complexe 
: Furin-like Golgi protease 
: ER signalases 
Enzymes involved in 
post-translational 
processing 
	 
M 
E 
Host-derived lipids 
ssRNA genome 
~ 11 kb 
Capsid 
3’ 
N.R.
C  
Structural 
proteins 
Nonstructural 
proteins CAP 
5’ 
N.C.R 
~ 100 nt  
ssRNA possesses a single ORF of about 11,000 bases 
650 
nt 
(a) 
(b) 
6	 
	 
internal loop between two β-strands and it is buried under the protein interface.  At low 
pH, the protein is exposed to conformational changes (Rey et al., 1995; Lescaret al., 
2001). Modis and co-workers (Modis et al., 2003) have reported the cystallisation of the 
E protein from Dengue virus type 2 which has aectodomain soluble fragment (residue 1-
394) that is similar to tick-borne encephalitis (TBE) virus.The hydrophobic ligand lined 
by the residues in this dimeric crystal structureisreported to affect the pH threshold for 
fusion (Modis et al., 2003). In the crystal structureof the E protein, the detergent, n-
octyl-β-D-glucoside used in the crystallisation process was found to be in itsbinding 
pocket which indicatedthe hydrophobic nature of the binding site (Modis et al., 2003). 
This information could then be used to aid in the design of small molecules that will fit 
into the binding pocket of the E protein which may inhibit the fusion process and 
subsequently, inhibit the entry of the pathogenic microbes into the host cells. 
 
The non-structural protein, NS1, is a glycoprotein which was found to be 
important for virus viability.  In vitro infection has revealed the translocation of NS1 
into endoplasmic reticulum (ER) through a hydrophobic sequence that is localized at the 
C-terminal of E protein (Falgout and Markoff, 1995).  A homodimer of NS1 was 
formed and interacted with membrane in the ER (Winkler et al., 1989).  A fraction of 
NS1 protein was found to be enrolled in the early stage of viral replication by 
association with intracellular organelles (Mackenzie et al., 1996; Muylaert et al., 1997). 
T he NS1 protein was also found to be exported along the secretory pathway of the 
plasma membrane by remaining anchored to the glycophosphotidylinositol group 
(Jacobs et al., 1992) or as a soluble hexamer (sNS1) (Flamand et al., 1995; Crooks, 
1994). 
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The NS3 of DEN2 has multifunctional protein fragments that contain serine 
protease, NS2B/NS3 as well as helicase.   Optimal activity of the NS3 serine protease is 
required for the maturation of the virus.  In addition, the presence of the NS2B co-factor 
is found to be a pre-requisite for the optimal catalytic activity of NS3 (Bianchi and Pessi, 
2002 and references therein).  Studies has revealed that this second largest protein 
contained a serine protease catalytic triad within the terminal region of 180 amino acid 
residues which require 40 amino acid residues of NS2B for protease activity (Falgout et 
al., 1991; Arias et al. 1993; Jan et al., 1995).  The polyprotein precursor processing 
occurs co-translationally as well as post-translationally and is performed by either the 
host cell proteases, furin or signalases in association with the membranes of the 
endoplasmic reticulum or the viral protease. The protease cleaves the viral polyprotein 
at four junctions, NS2A-NS2B (Arg-Ser), NS2B-NS3 (Arg-Ala), NS3-NS4A (Lys-Ser), 
and NS4B-NS5 (Arg-Gly) where a pair of dibasic amino acids at the P2 and P1 
positions followed by a small, non-branched amino acid (Gly, Ala or Ser) at P1’ was 
found as the consensus of substrate cleavage motif (see Figure 1.2 for more details) 
(Yusof et al., 2000 and references therein).  In addition, the viral protease has been 
found to cleave internally within NS2A (Nestorowicz et al., 1994) and NS3 (Falgout et 
al., 1991).  The NS3 residues from 180 to 618 contain conserved motifs that were found 
in several NTPase and the DEXH family of RNA helicases.  The mutational and 
competitive experiments using ATP and its analog as substrate suggested that both 
RTPase and NTPase activities share the same active sites (Bartelma and Padmanathan, 
2002).  Here, the impaired helicase of dengue viruses was unable to replicate, implying 
the important role of NS3 protein in the flavivirus life cycle.  Two crystal forms of 
dengue virus type 2 NTPase/helicases at 2.4Å and 2.8Å, respectively, were reported by 
Xu and co-workers (Xu et al., 2005).  The crystal structure comprises 3 domains with an 
asymmetric distribution of charges on its surface and a tunnel that is enough to fit in a 
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single-stranded RNA.  Its catalytic mechanism was assisted by the presence of the 
divalent metal ion, when a sulfate ion was found at the NTPase active site. (Xu et al., 
2005). 
 
NS5, the largest non-structural protein of DEN2 (predicted to be of molecular 
weight 103-104 kD), is the most highly conserved protein among the flavivirus protein 
(Mandlet al. 1988).  It was found to have two enzymes, 5” RNA O-methyltransferace 
and RNA-dependant RNA polymerase, and that O-methyltransferace is involved in 5’ 
capping, whereas the latter is involved in viral replication in infected cells.  The crystal 
structure of NS5 that containing guanyltransferrase /methyltransferase (Egloff et al., 
2002) has been reported.  Kapoor and co-workers found NS3 and NS5 proteins to be 
present in infected cells as a stable complex (Kapoor et al. 1995), and that NS5 is able 
to trigger the NTPase activities of NS3 (Yon et al., 2005).  These findings may resemble 
the role of heterodimeric NS3-NS5 complex in unwinding double stranded RNA during 
replication process (Wahab et al., 2007). 
 
1.3 Serine Proteases 
 
At present, over 155,000 peptidase gene sequences have been classified into 52 
clans and 208 families.  Based on the MEROPS database, over thirty percent of the 
proteolytic enzymes are classified as serine proteases, withmore than 55,000 serine 
proteases grouped into 16 clans and 46 families (http://merops.sanger.ac.uk/cgi-bin/ 
statistics_index?type=P, 15 May 2010). The serine protease was named for its 
nucleophilic serine which plays a vital role in the hydrolysis of peptide substrates in the 
active sites. In the serine protease, this proteolytic mechanism is distinguished by the 
appearance of a catalytic triad that formeda proton shuttling relay (Hedstrom, 2002). For 
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example, the catalytic triad in the serine protease, chymotrypsin, comprises Ser-195, 
His-57 and Asp-102.  The proteolytic mechanism of the serine protease will be 
described further in the section below. 
 
Serine proteases are widely distributed in all form of cellular life including viral 
genomes. Chymotrypsin-like proteases that classified under Clan PA are the most 
abundant serine proteases (Rawlings et al., 2010).  There are many important 
mammalian physiological processes that involve chymotrypsin-like proteases, such as 
digestion, hemostasis, reproduction, signal transduction, apoptosis, and the immunity 
responses (Hedstrom, 2002 and references therein). 
 
1.3.1 Dengue Virus NS2B/NS3 Serine Protease 
 
When the NS2B/NS3 serine protease was found to be important in the 
polyprotein processing in dengue virus, many approaches and efforts were made to 
understand the mechanism, structure and molecular interaction between the serine 
protease of NS2B/NS3 complex and its substrates.  The minimum domain size required 
for protease activity of the 69-kD NS3 protein has been mapped to 167 residues at the N 
terminus (Li et al., 1999). The virus sequence alignments analysed revealed that 
structural motifs as well as the characteristic catalytic triad (His-Asp-Ser) of 
mammalian serine proteases are conserved in all flaviviruses (Bazan and Fletterick, 
1989; Gorbalenya et al., 1989).  
 
Sequence comparison among the serine proteases and mutational analysis 
verified that a catalytic triad of NS2B/NS3 comprised of the residues His51, Asp75, and 
Ser135, and that replacement of the catalytic Ser135 residue by alanine resulted in an 
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enzymatically inactive NS3 protease (Yan et al., 1998). The presence of a peptide co-
factor is essential for optimal catalytic activity of the flaviviral proteases with natural 
polyprotein substrates (Bartenschlager et al., 1995; Chambers et al., 1991). 
 
Although the dengue virus NS3 protease exhibits NS2B-independent activity 
with model substrates for serine proteases such as N-α-benzoyl-L-arginine-p-
nitroanilide, the enzymatic cleavage of dibasic peptides is markedly enhanced in 
NS2B/NS3 complex.  In addition, the presence of the NS2B co-factor has been shown 
to be an absolute requirement for trans-cleavage of a cloned polyprotein substrate 
(Yusof et al, 2000). A genetically engineered NS2B(H)-NS3pro protease containing a 
non-cleavable nonamer glycine linker between the NS2B activation sequence and the 
protease moiety exhibited higher specific activity with para-nitroanilide peptide 
substrates than the NS2B(H)-NS3pro molecule (Leung et al., 2001). The NS2B-NS3pro 
protease incorporating a full-length NS2B cofactor sequence could catalyze the 
cleavage of 12-mer peptide substrates representing native polyprotein junctions 
(Khumthong et al., 2002; Khumthong et al., 2003).  
 
A model of the NS2B/NS3 dengue virus protease was first constructed through 
homology modeling using the crystal structure of HCV NS3/4A complex as template by 
Brinkworth and co-workers, with the suggestion that the 40 amino acid residues of 
dengue virus NS2B co-factor could be reduced to 12 hydrophobic residues (Brinkworth 
et al., 1999).   Experimental data on hepatitis C virus protease showed some structural 
and mechanistic explanations for the protease activation by its co-factor, where the 
NS4A co-factor was found to affect the folding of the NS3 protease.  This resulted in 
the conformational rearrangements of the N-terminal 28 residues of the protease and a 
strand displacement that lead to the formation of a well-ordered array of three β-sheets 
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with the co-factor as an integral part of the protease fold (Kim et al., 1996; Yan et al., 
1998). These conformational changes reorient the residues of the catalytic triad making 
it more favourable for proton shuttling during proteolytic process.  
 
Mutational analyses revealed the importance of several amino acid residues that 
are highly conserved among the flaviviruses, where 5 putative substrate binding 
residues (Asp-129, Phe-130, Tyr-150, Asn-152 and Gly-153) were proposed (Valle and 
Falgout, 1998). Computer modeling study of a substrate binding at the catalytic triad of 
the crystal structure of NS3 without its NS2B cofactor revealed that Gly-133 and Ser-
135 to be the most likely to form the oxyanion hole (Murthy et al., 1999).  Hydrogen 
bonding interactions have been observed between the main chain of P1 and P2 residues 
with appropriate main chain atoms of Gly-153 and Asn-152 to generate the short section 
of β-sheet common in serine protease-inhibitor interactions (Read and James, 1986). 
Three residues, Ser-131, Tyr-150, and Ser-163, are within the S1 pocket. A serine side 
chain at P1’ fits into the S1’ pocket formed by the catalytic His-51 and Ser-135 and 
residues Gly-35, Ile-36, and Val-52. The Oε1 atom of Asn-152 forms a salt 
bridge/hydrogen bond with Nε of the P2 Arg in the modeled complex (Murthy et al., 
1999). 
 
Although the crystal structure of DEN2 NS3 has been reported (Murthy et al., 
1999), the absence of NS2B cofactor therein makes the mechanism of proteolytic 
process activation unclear. The orientation of the carboxyl side chain of Asp-75 away 
from His-51 in the catalytic triad of NS3 crystals formed an open conformation that may 
lead to the inefficiency of proteolytic activity. 
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1.3.2 Mechanism of action  
 
Proteases, or proteinases are enzymes that recognise protein or peptide as their 
substrates and cleave these substrates by hydrolysing their amide bonds. Classification 
of the proteases (serine, aspartic, cysteine and metallo protease) is made after their 
critical amino acid residue used in the hydrolysis process. For dengue virus, the 
NS2B/NS3 complex is classified as chymotrypsin-like serine protease that has 3 critical 
amino acid residues (Ser135, His51, and Asp75) in the active site for catalytic process.  
 
Using chymotrypsin as an example, the mechanism of proteolysis by serine 
protease is illustrated in Figure 1.3 (Murrays et al., 2003).  From the carboxyl group of 
Asp-102, the electron-rich group is transferred through the cyclic amine of His-57 via a 
hydrogen bond, causing the hydroxyl group of Ser195 to become more nucleophilic and 
ready for catalytic proteolytic process.  When the peptide substrate moves into the 
active site, the nucleophilic hydroxyl of Ser-195 attacks the scissile electron-deficient 
carbonyl of the amide bond in the substrate, and subsequently forming the hemiketal 
tetrahedral intermediate which is stabilised by an oxyanion hole.  Proton transfer from 
the charged His-57 to the substrate caused the amide bond to break and thereafter, 
releasing the C-terminal product (the amine).  An acyl-enzyme complex with the N-
terminal product bound covalently with hydroxyl of Ser-195 is also formed.  Water then 
act as a nucleophile to attack the carbonyl of the ester forming thehemiketal tetrahedral 
intermediate which is stabilised by an oxyanion hole. The breakdown of the hemiketal 
intermediate was then initiated by the proton transfer from His-57, yielding the N-
terminal product (carboxylic acid) and regeneration of catalytic triad that is ready for 
the next substrate cleavage. All the catalytic process is promoted under acidic or basic 
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catalysis of His-57 and Asp-102, with the help of the backbone N-H groups of the Ser-
195 and Gly-193 in the oxyanion hole during the formation of hemiketal tetrahedral 
intermediate. 
Figure 1.3: Proteolytic process at the catalytic triad of serine protease 
 
1.4 Approaches towards Dengue Virus Inhibition 
1.4.1 Attenuated vaccine 
  
Vaccine development is a very popular and effective method for human to fight 
against diseases, especially when the disease is endemic. Several developed vaccine 
such as hepatitis B, rubella, tetanusare shown to be effectively able to control these 
diseases.  
 
Initiative such as the production of a live-attenuated vaccine in suckling mouse 
brain (Hotta, 1957; Sabin and Schlesinger, 1945; Schlesinger et al., 1956;   Wisseman et 
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al., 1963) would be useful in diseases such as DHF/DSS since effective vaccine could 
be produced for protection against it while not making the population susceptible. 
Under US army sponsorship, the attenuated dengue 1, 2 and 4 vaccines have 
beenproduced from tissue culture and tested in human (Institute of Medicine, 1986).   
 
1.4.2 Therapeutic agents: virus inhibitor 
 
HIV serine protease inhibitor was amongst some examples of commercially 
available medication for human administration (West and Fairlie, 1995).   In other 
examples, two heptapeptides containing amino boronic acid has also been shown by 
Dunsdon and co-workers (Dunsdon et al., 2000) to inhibit the activities of HCV’s NS3 
protease.  Such successful cases of inhibiting viral replication by employing inhibitor 
design based on their related serine proteases has attracted more studies of serine 
proteases related diseases in order to find the best serine protease inhibitor to inhibit 
viral infection.  It is also important to have the inhibitor that is only selective towards 
the targeted protease in order to minimize the risk of adverse effects. 
 
1.4.3 Dengue Virus NS2B/NS3 Serine Protease inhibitor 
 
Serine proteases were recognised as a useful target for their inhibitor design and 
discovery in the recent trend of drug discovery development work.  While there have 
not been many reports on bioactive small molecules against dengue viruses, there have 
been some work in progress in this area.  Leung and co-workers synthesised several 
small peptide substrates (Figure 1.4) with potent inhibitory activity against 
CF40.gyl.NS3 protease (Leung et al., 2001).Chanprapaph and co-workers designed 
synthetic tripeptides such as KKR that were found to act as competitive inhibitors for 
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NS3 serine protease with the substrate GRR coupled with aminomethyl coumarin (or 
AMC)(Chanprapaph et al., 2005) while Ganeshand his co-workers have identified five 
small molecules with inhibitory activity against the NS2B(H)-NS3 protease (Figure 1.5) 
through molecular docking experiments (Ganesh et al., 2005).   Small molecules from 
natural product extracts have also been reported to exhibit inhibitory activities against 
NS2B/NS3 dengue serine protease.  For example, 4-hydroxpanduratin A (1) and 
panduratin A (2) extracted from Boesenbergia Rotunda, have been reported to 
competitively inhibit the activity of the DEN 2 serine protease (Tan et al., 2006). 
 
	 
Figure 1.4: Small peptide substrate. A:AcGRR-α-keto-SL-CONH2, B: AcGRR-
CHO(Leung et al., 2001) 
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Figure 1.5: Structures of the compounds with terminal guanidinyl group that have 
potential inhibition activity against DEN2 NS2B/NS3 serine protease(Ganesh et al., 
2005) 
 
Many researchers have taken the advantage of the advancement in 
computational techniques in drug design and development work.  There are many 
successful examples from the computer-aided drug design of the HIV protease which 
provides many drug candidates for further phase of processes. Amongst them, 
Oscarsson and co-workers utilised the crystal structure of HIV protease and the 
substrates information to design a tetrahyrofuran P2 analogues that inhibit HIV protease 
in nanomolar scale (Oscarsson et al., 2003).  More recently, Durdagi and co-workers 
developed a series of fullerene derivatives based on an in silico virtual screening study 
on these compounds. The compounds with good binding scores were found to be active 
on HIV protease when subjected to biological studies (Durdagi et al., 2009).  
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1.5 Aims and Objectives 
 
Through the understanding of the structure and conformation of the DEN2 
serine protease and its binding interactions to the inhibitors, the new drug candidate 
could be designed.  Amongst the aim of this work is to use computational technique to 
study the molecular binding interactions between the DEN2 NS2B/NS3 serine protease 
with competitive inhibitors observed in vitro (Tan et al., 2006).  Subsequently, new 
ligands with better inhibitory activities towards the NS2B/NS3 DEN2 serine protease 
will be designed and synthesised.  The designed molecule will then be screened 
tovalidate the template used for the design of novel active molecules. 
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CHAPTER 2 
HOMOLOGY, DOCKING AND NEW LIGAND DESIGN OF DEN2 
NS2B/NS3 SERINE PROTEASE INHIBITION 
 
2.1 Molecular Modelling in Drug Design 
 
In the past few decades, from new compounds to new drug discovery, methods 
employed by scientist were mostly on trial-and-error basis. Million of compounds, from 
natural products to chemically-synthesized, have been screened against targeted systems 
to obtain a lead compound for further development.  Rationalisation for screening of 
compounds in searching for bioactivity is usually based on the experience of the 
researchers and/or by chemical intuitions. However, this routine work for drug 
discovery and development is very expensive, laborious, time consuming and perhaps in 
the context of modern drug design and development research, somehow inelegant. In 
spite of this, this “classical” approach has provided several successful drugs, from 
minor infections to the life-threatening diseases. For instance, Taxol® (Figure 2.1), a 
well-known compound to date that is commonly used to treat cancer, was firstly 
isolated by Wall and co-worker and reported their findings in 1971 (Wani et al., 1971)  
 
 
Figure 2.1: Structure of Taxol®  
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Today, classical drug discovery approach is often coupled with more rational 
approaches, whereby structural information is channelled to the processes involved in 
the underlying illness. For this, one begins with identifying a related molecular target 
(enzyme, receptor, etc) that causes the problem or disease, understanding of their 
mechanism, followed by selecting a suitable drug candidate or a lead compound that 
interacts in the biological activity of the disease or the target.  In the process of 
approaching rational drug design work against diseases, molecular modelling has 
become a powerful tool.  
 
Molecular modelling can simply be defined as utilisation of computational 
resources to study, model and or, to mimic the molecules behaviour and molecular 
system. Molecular modelling involves computational approaches combined with multi-
disciplinary knowledge, incorporating the field of physics, chemistry, biology and 
mathematics.  Such techniques used to be restricted to a small number of scientists with 
access to the computer hardware and software, where the programs, systems and 
maintenance were all done by themselves. Today, however, with the fast developing 
computing technology, computing facilities cost has become relatively low, yet still 
powerful enough to handle complicated calculations.  Computational methods and 
molecular modelling are now very popular techniques in many academic institutions as 
well as world leading pharmaceutical companies.  There are now many molecular 
modelling softwares available as open source for academic institutions which have 
benefited many scientists since they do not need to write their own programs but just to 
understand the working operations with some backgrounds on the software 
development. Molecular modelling is now blossoming with many successful 
approaches on drug discovery and development research.  This can be seen by the 
exponential rise in the number recent scientific publications incorporating molecular 
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modelling techniques. This field of science is now more matured.  However, there is 
still room for improvement in which more robust and more complicated molecular level 
calculations are required in drug discovery research.  In order to make the drug design 
approach more rational with help of molecular modelling, the homology modelling and 
docking were used in this work. 
 
2.2 Homology Modelling 
 
  In the absence of a crystal structure of a protein of interest, homology modelling 
is one of the approaches used to predict the protein structure.  Homology modelling, or 
comparative modelling, is a structural prediction method that is commonly used for 
protein structure prediction and building.  Here, the amino acid sequence of the protein 
of interest is aligned with one or more known protein structures (known as "templates") 
(Blundell et al., 1987; Sali, and Blundell, 1993, Fiser et al., 2002;).  The protein of 
interest and the templates used usually contain structurally conserved region when they 
are aligned with proteins from the same family that have nearly identical structures.  
The observed sequence similarities usually imply the significant structural similarity 
since the three dimensional structures of proteins from the same family is more 
conserved than their primary sequences (Lesk, Chothia, 1980).  The aligned sequences 
and the template structure are then used to build a structural model of the targeted 
protein (protein of interest).  Homology modelling is the only method remaining 
technique that can reliably predict a protein structure with an accuracy that is 
comparable to a low-resolution experimentally determined structure (Marti-Renom et 
al., 2002). 
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Basically, homology modelling procedure consists of four sequential steps: 
template selection, target-template alignment, model construction, and model 
evaluation. Template selection is usually initiated by PDB searching (Westbrook et al., 
2002) of known protein structures, using the target sequence as a query of the search. 
This search is done by comparing the targeted protein sequence with the sequence of 
each of the structures of proteins in the database (Fiser and Sali, 2003).  
 
2.2.1 Target-template selection 
 
A list of potential templates is obtained from the search earlier which would 
contain one or more templates that should be appropriate for the particular modelling 
problem.  Since the quality of the model generated increases with the overall sequence 
similarity of the selected template to the target and decreases with the number and 
length of gaps in the alignment, the best template selected would be the structure with 
the highest sequence similarity to the modelled sequence.  Occasionally, one should 
also consider the similarity between the “environment” (eg, solvent, pH, ligands, and 
quaternary interactions) of the template and the environment in which the targeted 
protein needs to be modelled.   
 
In addition, a template bound to the same or similar ligands as the modelled 
sequence is the best choice of template used for the modelling.  Besides, the resolution 
and R-factor of a crystallographic structure and the number of restraints per residue for 
an NMR structure is the key to the accuracy of the structure.  Thus, the highest 
resolution should generally be selected.  The purpose of a comparative model 
generation could sometime alter the template. On the other hand, the template that 
contains a similar ligand to the targeted protein is probably more important than the 
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resolution of the template itself.   For the generation of a model to be used for the 
analysis of the geometry of an active site in an enzyme, it may be preferable to use a 
high-resolution template structure (Srinivasan and Blundell, 1993; Sanchez and Sali, 
1997). 
 
2.2.2 Target-template alignment 
 
 Following a suitable template selection, an alignment method is used to align 
the target sequence with the template structures (Briffeuil et al., 1998; Baxevanis, 1998; 
Smith, 1999).  The alignment is easier and more reliable when the target and template 
protein have sequence identity higher than 40%.  For sequence identity below 40%, 
regions that have low local sequence similarity become frequent (Saqi et al., 1998). The 
sequence alignment is said to be difficult or in the “twilight zone” when their sequence 
identities are less than 30% (Rost, 1999). In such cases, alignments may contain 
increasingly large number of gaps and alignment errors, regardless of whether they are 
prepared automatically or manually.  Therefore, it is worth the effort to get the most 
accurate alignment possible because there is no current comparative modelling method 
available to recover from an incorrect or bad sequence alignment. Multiple sequence 
and structure alignment may help in the more difficult target-template sequence 
alignment. There are various web-based protein sequence alignment, including 
CLUSTAL (Thompson et al., 1994; Higgins et al., 1996), FASTA3 (Pearson et al., 
1990), BCM (Smith et al, 1996), BLAST2 (Altschul et al., 1990), BLOCK MAKER 
(Henikoff et al., 1995) and MULTALIN (Corpet, 1988). 
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2.2.3 Model construction 
 
After the sequence alignment between targeted protein and template were 
determined, a three-dimensional (3D) protein model is built. There are various ways to 
construct a target protein.  One of the very early time and still widely used method is the 
rigid body assembly (Browne et al., 1969; Greer, 1990; Blundell et al., 1987). 
Modelling by segment matching is another method that depends on the approximate 
positions of conserved atoms in the templates (Jones and Thirup, 1986; Claessens et al., 
1989; Levitt, 1992). Yet another method involves modelling by satisfaction of spatial 
restraints, where the distance geometry or optimization techniques were used to fulfil 
spatial restraints obtained from the alignment (Sali and Blundell, 1993 and references 
therein). All model building methods are said to be accurate and relatively similar when 
used optimally (Marti-Renom et al., 2002).  As mentioned earlier, other factors such as 
template selection and target-template sequence alignment will give more impact to the 
model accuracy, especially when the models are based on less than 40% sequence 
identity to the templates (Marti-Renom et al., 2000 and references therein). 
MODELLER 6V2, the comparative modelling software based on satisfaction of spatial 
restraints was used in this study due to its popularity on various homology modelling in 
many recent works (Sali and Blundell, 1993). 
 
2.2.4 Model evaluations 
 
The constructed 3D protein model of interest has to be evaluated to check for its 
accuracy. The evaluation can be performed on either individual regions or the whole 
protein itself. The folding and stereochemistry of the model will first be checked.   The 
reliability of the generated protein model is generally increased depending on the 
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following factors; i.e. when the sequence similarity is increased between the target and 
template, the pseudo-energy Z-score (Sippl, 1993; Sanchez and Sali, 1998) is increased, 
and conservation of the key functional or structural residues in the target sequence is 
increased.  
 
Stereochemistry of the model can be verified with the help of some commonly 
used programs such as PROCHECK (Laskowski et al., 1998), PROCHECK-NMR 
(Laskowski et al., 1996), AQUA (Laskowski et al., 1996), SQUID (Oldfield, 1992), and 
or, WHATCHECK (Hooft et al., 1996).  These programs are available to check the 
bond lengths, bond angles, peptide bond and side chain ring planarities, chirality, main 
chain and side chain torsion angles, and clashes between non-bonded pairs of atoms in a 
built protein model.  Program such as VERIFY3D (Luthy et al., 1992), PROSAII 
(Sippl, 1993), HARMONY (Topham et al., 1994), and ANOLEA (Melo and Feytmans, 
1998) are amongst the methods available for inspecting spatial features of built model 
based on 3D profiles and statistical potentials of mean force (Sippl, 1990; Luthy et al., 
1992). Errat (Colovos and Yeates, 1993) is used to check the pairwise non-covalently 
bonded interactions of carbon (C), oxygen (O) and nitrogen (N) atom (CC, CN, CO, 
NN, NO, and OO). The environment of each residue in a built model will be evaluated 
with respect to the expected environment found in the high-resolution X-ray structures. 
The theoretical validity of the energy profiles will then enable regional error detection 
in the models (Fiser et al., 2002).   
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2.3 Molecular Docking 
2.3.1 Introduction 
 
Molecular docking is one of the molecular modelling techniques that is used to 
predict binding interactions and molecular orientation between macromolecules (mainly 
are proteins, enzymes, DNA or RNA) and other molecules (either proteins, nucleic 
acids or small drug-like molecules), where the bindings are later evaluated 
geometrically and energetically.  
 
It is known that the ability of macromolecules to interact with small molecules 
affects their biological function.  It has also been observed that the binding between 
ligands and nucleic acids to form supra-molecular complexes helps in the control of 
many biological pathways.  Due to these observations, molecular docking has become 
very popular and has significantly grown in its applications in computational biology 
such as in rational drug design research.  
 
Molecular docking was inspired by the “lock-and-key” model that was first 
proposed by Emil Fisher in 1890 to represent protein and ligand interactions. The 
suitable “key” that is able to open up a “lock” from a given a set of keys mimics the 
protein that behave as the “lock” and the ligand as the “key”.  Current docking methods 
treat protein structures as rigid entities, leaving the ligand to be flexible during the 
binding process to find the best spatial and energetic fit to the protein’s binding site.  It 
is therefore possible to use molecular docking with different “keys” (ligands) that can 
bind to the same protein and optimise it in order to discover the “best-fit” ligand that 
binds to a protein of interest. 
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 Two main matters need to be considered while approaching the molecular 
docking protocols; namely searching algorithm and scoring function (Taylor et al., 
2002).  For searching algorithm, there are two basic approaches that are commonly 
employed.  The first approach uses the matching techniques that describe the protein 
and the ligand as complementary surfaces. Matching methods resembles the active site 
of a protein model that is usually rigid and its binding surface was described by 
including hydrogen bonding sites and sites that are sterically accessible. Attempts to 
dock various ligands of interest were then performed into the protein as a rigid body 
based on its geometric matching to the active site. This approach is typically fast and 
robust and allows a quick scan through thousands of ligands in matter of seconds and 
determines whether they can bind to the active site, regardless of the ligand size. One of 
the most successful examples of this approach is DOCK which has been used efficiently 
to screen an entire chemical database for lead compounds rapidly (Kuntz et al, 1982; 
Shoichet and Kuntz, 1993).  Unfortunately, DOCK is unable to accurately estimate the 
dynamic changes in the protein-ligand conformations.  However, recent developments 
have allowed molecular docking methods to investigate ligand flexibility.  
 
The other approach involves modelling of ligands by positioning it randomly 
outside the protein and exploring their translations, orientations, and conformations 
until an ideal site is found. Compared to the matching technique earlier, this technique 
is relatively more time consuming. However, they allow flexibility within the ligand to 
be modelled and a more detailed molecular mechanics could be utilised to calculate the 
energy of the ligand when it interacts with the putative active site. This approach 
mimics the actual protein-ligand interaction better because the total energy of the 
system is calculated following every move of the ligand in the protein’s active site. One 
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of more popular software that is based on this approach is AUTODOCK, which is 
developed by Olson and his co-workers at the Scripp’s Institute, San Diego.  
 
 Search algorithm could be performed to produce an optimum number of 
configurations that contained experimentally determined binding modes. These 
configurations are evaluated using scoring functions to search all possible binding 
modes between the ligand and protein.  
 
It is impractical to search through all degrees of freedom (translational and 
rotational) for the protein-ligand molecules interaction due to the gigantic size of search 
space that require long computing duration with the recent computing resources and 
technology (Taylor et al., 2002).  As a compromise, the amount of search space 
examined with the computational expenses, constraints, restraints and approximations 
were applied while sampling the search space.  This helps to reduce the dimensionality 
of the problem while locating the global minimum efficiently.  Some common search 
algorithms include molecular dynamics, Monte Carlo methods, genetic algorithms, 
fragment-based methods, point complementary methods, distance geometry methods, 
Tabu searches and systematic searches. It is also possible to use a combination of search 
algorithms. 
 
 After all possible bound conformations of ligands have been explored with the 
appointed search algorithm, a scoring function is required to rank all ligands to 
determine the plausible binding mode. Usually, scoring function includes 
approximation of the free energy of binding between the ligand and the protein (Leach, 
2001) by adding entropic terms to the molecular mechanics equations as shown below: 
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ΔGbind = ΔGvdw + ΔGhbond + ΔGelec + ΔGconform + ΔGtor + ΔGsolv 
 
where ΔGvdw is dispersion/repulsion energy, ΔGhbond is hydrogen bonding energy, ΔGelec 
is electrostatic energy, ΔGconform is the energy deviations arises from conformational 
change, ΔGtor  corresponds to the energy changes due to the restriction of internal rotors 
and global rotation and translation; and ΔGsolv is attributed by desolvation upon binding 
and the hydrophobic effect  (solvent entropy changes at solute-solvent interfaces). The 
first four terms are derived from molecular mechanic, and the latter term is the most 
challenging (Morris et al., 1998). 
 
The complexity of the scoring function is usually reduced in order to adapt the 
computational expenses.  This often resulted in distorting its accuracy.  There are 
various force fields used in scoring functions, ranging from molecular mechanics force 
fields such as AMBER (Cornell et al., 1995), OPLS (Jorgensen and Tirado-Rives, 
1988) or CHARMM (Brooks et al., 1983), to empirical free energy scoring functions 
(Eldridge et al., 1997) or knowledge based functions (Muegge and Martin, 1999). 
Usually, there are two ways to define the scoring functions in most docking methods. 
One uses the scoring function to rank a particular ligand conformation, followed by the 
modification of the ligand conformation by a search algorithm, and the scoring function 
is again used to rank the newly generated conformation. Another is by applying the 
scoring function in a two-stage scoring function:  first, the search strategy is directed by 
a reduced scoring function.  This is followed by a more rigorous scoring function to 
rank the various conformer generated from the studied ligand which is directed to the 
putative binding site as determined by the reduced scoring functions.  
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The second method is modified to adapt to the computational expenses by 
omitting the terms such as electrostatics and only consider some binding interactions 
(eg., hydrogen bond), as well as making assumptions on the energy hypersurface.  Other 
term such as the solvation effect, is either neglected or defined in a snap-shot fashion, 
where it involves the generation of structures in vacuo, followed by ranking with a 
scoring function that includes a solvent model (Taylor et al., 2002).  
 
2.3.2 AUTODOCK 
 
 AUTODOCK is one of the widely used molecular docking software developed 
by Olson and his co-workers at the Scripp Institute.  AUTODOCK is a flexible 
ligand-oriented docking technique by random positioning of the ligand outside the 
protein and exploring its translations, orientations, and conformations to get the ideal 
binding site. The original search algorithm employed was the Metropolis method, or 
more commonly known as the Monte Carlo simulated annealing (SA).  This algorithm 
directs the ligand to perform a random walk in the spaces around the protein while the 
protein remained static throughout the simulation. A small and random displacement 
(translation of its centre of gravity or root atom; orientation; and dihedral angles around 
each of its flexible bond) is applied to each of the degrees of freedom of the ligand 
while each step in the simulation is performed. As a result, a new conformer is 
generated and its energy is evaluated using the grid interpolation procedure. Different 
searching methods which have been claimed to have a better accuracy than SA have 
been developed. These searching methods are called Genetic Algorithm and 
Lamarckian Genetic Algorithm, which are outlined below. 
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2.3.3 Searching methods for AUTODOCK 
 
The version of AUTODOCK (AUTODOCK 3.0) (Morris et al., 1998) used in 
these studies employed a few options of search algorithm. While maintaining its initial 
Monte Carlo simulated annealing (SA) searching method, genetic algorithm (GA), local 
search (LS) were also used to perform energy minimization.  In addition, the hybrid 
methods of GA and LS based on the work of Hart’s and Belew’s co-workers (Hart et 
al., 1994; Belew and Mitchell, 1996) was used.  This hybrid method is also termed as 
“Lamarckian genetic algorithm” (LGA).   
 
Lamarckian was initiated by Jean Batiste de Lamarck whose postulated that 
phenotypic characteristics acquired during and individual’s lifetime can become 
heritable traits (discredited) (Lamarck, 1914).  
 
 GA (Holland, 1975) is a mathematical language that used the idea of Darwin’s 
theory of evolution, which was initially used to explain the natural genetics and 
biological evolution.  In AUTODOCK, the translation, orientation, and conformation of 
the ligand with respect to the protein are defined by a set of values called ligand’s “state 
variable”. In the context of GA, each state variable corresponded to a “gene”, the 
ligand’s state corresponded to the “genotype”, whereas its coordinates corresponded to 
the “phenotype”. The total interaction energy of the ligand with the protein which 
corresponded to the “fitness” is calculated using the energy function. The “crossover” 
processes then occur to generate new individuals that inherit genes a random pair of 
individuals.  “Mutation” may happen to some offspring to alter their “genes” for 
variation.  The “elitist” strategy is applied when “selection” is made from the offspring 
of the current generation based on the individual’s “fitness” calculated from the 
implemented scoring function.  Offspring that is better suited to their environment 
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(lowest energy) will proceed to reproduce new generations, whereas poorer ones will 
die or stop from reproducing. (Morris et al., 1998) 
 
The crossover or binary mutation for new individual generation being inefficient 
due to the generation of value that is outside of the domain of interest.  Thus, the GA 
search performance is improved by implementing a local search method. The local 
search method is based on Solis and Wets’ protocol (Solis and Wets, 1981).  This 
protocol facilitates the torsional space search which does not require gradient 
information about the local energy landscape. The local search method is more adaptive 
because the step size can be adjusted according to the recent history of the calculated 
energies: a user-defined number of consecutive failures or increases in energy doubled 
the step size; whereas the success will reduce the step size into halves. Putting the GA 
and LS methods together resulted in the hybrid method called Lamarckian Genetic 
Algorithm. This searching method is claimed to enhance AUTODOCK performance 
and allows more degrees of freedom.  In addition, the force field used in docking could 
also be used for ligands energy minimization.  For each new population, in which GA 
uses two point crossover and mutation operators, a user-determined fractions will 
undergo a local search procedure with a random mutation operator where the step size is 
adjusted to give an appropriate acceptance ratio (Morris et al., 1998).  
 
In summary, a generation of new conformers would have undergone five stages 
consecutively: mapping and fitness evaluation, selection, crossover, mutation, and elitist 
selection.  These processes were repeated until a user-defined total number of final 
conformers are achieved.  Three different search algorithms (SA, GA and LGA) were 
tested on seven crystal structure of protein-ligand complexes.   GA and LGA showed 
better results than SA, with their lowest energy structures are within 1.14 Å RMSD of 
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the crystal structure (Morris et al., 1998).  Figure 2.2 showed the workflow of LGA 
search method. 
 
 
 
Figure 2.2: The protocol of Lamarckian Genetic Algorithm (LGA) search method. The 
lower horizontal line represents the space of the phenotypes, whereas the upper one 
represents the space of the genotypes. The mapping function maps the genotypes to 
phenotypes. F(x) represents fitness function. The genotypic mutation operator from the 
parent’s genotype with the corresponding phenotype is shown on right-hand side of the 
diagram, whereas the local search operator is shown on the left-hand side. Searching is 
usually performed in phenotypic space to gain information about the fitness value. With 
sufficient iterations of the local search to arrive at a local minimum, an inverse mapping 
function is then used to convert phenotype to its corresponding genotype. AUTODOCK 
perform local search by continuously converting the genotype to the phenotype, hence 
inverse mapping is not required, where the genotype of the parent is replaced by the 
resulting genotype, in accordance with Lamarckian principles (Source: Morris et al., 
1998) 
 
 
2.3.4 Scoring function of AUTODOCK 
 
Scoring function in AUTODOCK is implemented to evaluate the “fitness” or 
how good the docked energy between ligand and protein is. Five terms were 
implemented in AUTODOCK based on the thermodynamic cycle of Wesson and 
Eisenberg (Wesson and Eisenberg, 1992): a Lennard-Jones 12-6 dispersion/repulsion 
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term for Van der Waals potential energy calculation; a directional 12-10 hydrogen bond 
term for hydrogen bonds modelling; a coulombic electrostatic potential; a term 
proportional to the number of sp3 bonds in the ligand to represent unfavourable entropy 
of ligand binding due to the restriction of conformational degrees of freedom; and a 
desolvation term that is derived from inter-molecular pair wise summation combining 
an empirical desolvation weight for ligand carbon atoms and a pre-calculated volume 
term for the protein grid (Taylor et al., 2002).  The empirical free energy coefficients of 
these five terms are derived using linear regression analysis from a set of 30 protein-
ligand complexes with known binding constants.  AMBER force field is implemented 
into AUTODOCK for the protein and ligands parameters (Morris et al., 1998).  
 
2.3.5 Programs in AUTODOCK 
 
To run molecular docking using AUTODOCK, there are three main programs 
involved: Autotors, Autogrid, and Autodock. “Autotors” is used to define the torsion in 
the ligands by determining their bonds, either by making all bonds rotatable, selective 
rotatable or rigid; and defining the root atom (fixed portion of the ligand, from which 
rotatable ‘branches’ sprout).  
 
“Autogrid” is used on protein (or termed as “macromolecule” in AUTODOCK) 
to build a three dimensional grid of interaction energies map based on the atom type of 
the protein target. This grid map is a three dimensional lattice of uniformly spaced 
points that positioned surrounding or is centered in the site-of-interest of the protein. 
Each point contains a probe atom that has the pre-calculated affinity potential energy for 
each atom type of interest that it is assigned to (Morris et al., 2001).  By using a distant-
dependent dielectric function (Mehler and Solmajer, 1991), the grid map is able to 
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include the electrostatic interactions by interpolating the electrostatic potential and by 
multiplying the atom charges. The pre-calculated energy functions stored in the grid 
map makes the protein-ligand binding interaction energy calculation solely dependent 
on the number of atom in the ligand, hence accelerating the molecular docking in 
AUTODOCK. 
 
Finally, the “Autodock” is the program that execute the docking simulation 
based on user-defined parameters (ligands, searching methods, number of docking runs, 
etc.) which gave the output of the “elitist” (best conformer) in terms of its docked 
energy, estimated free energy of binding, estimated inhibition constant, internal energy 
of ligand, together with some user defined analyses, such as clustering histogram, 
ranking of found conformers and rmsd.  
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2.4 Materials and Methods 
2.4.1 Homology model of DEN2 NS2B/NS3 Serine Protease 
 
Homology model of NS2B/NS3 of dengue virus type 2 was built using the HCV 
serine protease NS3/NS4A (pdb ID: 1jxp) as the template. The Modeller (mod6v2) 
software package was used to perform model building. The sequence alignment was 
done based on the published results of Brinkworth et al., 1999. The quality of the 
backbone of rough model generated from Modeller was then evaluated using 
PROCHECK (Laskowski et al., 1993), VERIFY3D (Bowie et al. 1991) and ERRAT 
(Colovos and Yeates, 1993) on the UCLA bioinformatics server 
(http://nihserver.mbi.ucla.edu/SAVES/, 16 April 2005).    Energy minimization (100 
steps of steepest decent plus 50 steps of conjugate gradient) was performed onto the 
model, using Hyperchem software package (Hypercube, Inc.) to reduce the bumps and 
bad contacts while keeping the backbone of the protein restrained. The model 
evaluation was then repeated. Figure 2.3 illustrated the workflow of this work 
performed. 
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Figure 2.3: Work flow of homology model construction for 3D structure of 
DEN2NS2B/NS3 serine protease 
 
2.4.2   Comparison of the homology model with crystal structures of and DEN2 
NS3 and HCV NS3/4A 
 
The similarities and differences of the structure and conformation around the 
catalytic triad in of the constructed homology model of DEN2 NS2B/NS3 serine 
protease were evaluated using the crystal structures of DEN2 NS3 (pdb id: 1bef) and the 
HCV NS3/NS4A (pdb id: 1jxp). 
 
2.4.3 Docking experiment using homology model  
 
The docking of three competitive bioactive molecules, 4-hydroxypanduratin A 
(1), panduratin A (2) and ethyl 3-(4-(hydroxymethyl)-2-methoxy-5-nitrophenoxy) 
propanoate (3) (termed as “ester (3)” in later discussion), onto the catalytic triad of the 
serine protease were performed using AUTODOCK 3.05 software package (Morris et 
Template: HCV serine protease crystal 
structure (pdb id:1jxp) 
Sequence alignment 
Homology modeling with Modeller 6v2 
Rough model 
3D structural verification (PROCHECK, 
VERIFY3D, ERRAT) 
Structure refinement                                                                   (100 steps 
Steepest Decent  + 50 steps Conjugate Gradient) 
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al., 1998). The homology model of DEN2 NS2B/NS3 protease molecule was added 
polar hydrogen atoms and its non-polar hydrogen atoms were merged to the heteroatom 
connected to them. Kollman charges were assigned and solvation parameters were 
added to this enzyme molecule. For the ligands, non-polar hydrogen atoms were merged 
with Gasteiger charges assigned. All rotatable bonds of ligands were set to be rotatable. 
Docking was performed using genetic algorithm and local search methods (or termed as 
Lamarkian Genetic Algorithm). A population size of 150 and 10 millions energy 
evaluations were used for 100 times searches, with a 60 x 60 x 60 dimension of grid box 
size and 0.375 Å grid spacing around the catalytic triad. Clustering histogram analyses 
were performed after the docking searches.  The best conformations were chosen from 
the lowest docked energy that populated in the highest number of molecules in a 
particular cluster with not more than 1.5 Å root-mean-square deviation (rmsd). The H-
bond, van der Waals and other binding interactions were analysed using Viewerlite 4.2 
(Accelrys Software Inc.). Figure 2.4 illustrated the workflow of the docking experiment 
was performed. 
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Figure 2.4: Workflow of performing docking experiment using AUTODOCK 3.05 
 
4-Hydroxy Panduratin A Ester 3 Panduratin A 
Competitive inhibitors 
Stereochemistry Justification  
and Geometry Optimization 
Input File Preparations  
for Docking Experiment 
(AUTODOCK 3.05) 
•Compute Gaisterger charges on 
polar H and unite non-polar H 
•Distinguish aromatic and aliphatic 
carbons 
•Choose root (auto) and rotatable 
bond (all rotatable) 
 
Ligand Macromolecule (Protease) 
•Add polar H, assign Kollman 
charges 
•Assign Stouten solvation 
parameters 
•Compute AutoGrid maps (60 x 
60 x 60 grid box size and 0.375 
Å grid spacing at active sites) 
AUTODOCK Input Parameters 
•Larmackian Genetic Algorithm-Local Search method  
•150 population size  
•10 millions energy evaluation  
•100 times of search 
•Perform clustering histogram analysis, with RMSD tolerance 1.5 Å 
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2.4.4 Design of the new ligand from the docked bioactive molecules 
 
The conformer of the studied molecule that has the lowest docked energy was 
extracted its coordinates and the binding interactions between molecules and protease 
were studied with the help of molecule viewer software, Viewer Lite, to locate the 
important interactions between protease and molecules. Superimpositions between the 
different docked molecules to the protease were performed to find the common and 
redundant functional groups among the docked molecules. The important fragments and 
functionalities were then implemented in the new deigned ligand. The designed ligand 
was then docked into the protease and the docked energy was reevaluated. 
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2.5 Homology Model of DEN2 NS2B/NS3 Serine Protease 
2.5.1 Results 
2.5.1.1 Homology model building and model evaluation  
 
In order to enable the in silico binding interaction study to be carried out, a 
homology model of DEN2 NS2B/NS3 serine protease was built based on the crystal 
structure of HCV NS3/NS4A serine protease. The model was built by spatial restrain 
that is applied in MODELLER 6v2 software. The built model was then refined by 
several minimisations and was sent to a web-based structural verification to gain details 
about the quality of the generated model. In this study, PROCHECK, VERIFY 3D and 
ERRAT was performed.  
 
In the Ramachandran plot obtained from PROCHECK (Figure 2.5), an overall 
100 % non-glycine residue was shown to be in the allowed region. This implies a good 
protein backbone structure and folding, where the distribution of the / angle of the 
model were within the allowed region.  
 
In addition, analysis of the homology model from VERIFY 3D (Figure 2.6) 
showed 90.4% of the residues having a 3d-1d score of greater than 0.2. This suggests a 
reasonable conformation of the residues in the model. However, the region with 3d-1d 
scores of lower than 0.2 was found in the range of Glu-91-Gln-110. This indicates a 
lower confidence in its conformations and folding, implying a lower homology between 
DEN2 serine protease and HCV serine protease in this particular region.  
 
Besides PROCHECK and VERIFY 3D, ERRAT was also used to examine the 
non-bonded structures of the protein model and to compare with a reliably high-
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resolution structures from the database of protein crystals. The DEN2 N2SB/NS3 
homology model showed about 77% overall quality factor of the sequence to be below 
95% rejection limit for each chain in the input structure (Figure 2.7). This indicated an 
improved three-dimensional profile of the protein after several minimisations, as 
compared to the pre-generated homology model (data not shown).  All these verification 
procedures performed on the NS2B/NS3 protease model indicated this model to have 
reached a satisfactory fold quality.  Thus, no further loop modelling was carried out on 
the model.  
 
 
Figure 2.5: Ramachandran plot of built homology model of DEN2 NS2B/NS3 complex 
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Figure 2.7: ERRAT analysis of DEN2 NS2B/NS3 homology model 
 
2.5.2 Discussions 
2.5.2.1Comparison of the homology model with crystal structures of DEN2 NS3 
and HCV NS3/NS4A 
 
Overall, the homology model showed almost the same folding pattern as that 
observed in the DEN2 NS3 crystal structure. One alpha-helix and 6 beta sheets are 
observed in the first domain of both homology model as well as DEN2 NS3 crystal 
structure (Figure 2.8). The differences between two models, however, were observed in 
the second NS3 domain where more loop regions were observed in the crystal structure 
of NS3 compared to those observed in the homology model. In addition, only one alpha 
helix and 7 beta sheets in C terminal region was observed in the crystal structure for 
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NS3, whilst one extra beta sheets in the same domain was observed in the homology 
model.   
 
In the reported crystal structure of HCV serine protease, the NS3 protein is 
incorporated with the NS4A residues as co-factor into the N-terminal domain -sheet, 
thusled to a more rigid and precise framework for “prime-side” substrate binding 
channel residueswhich provided a better catalytic cavity making the NS3 enzyme more 
active in proteolytic process (Kim et al., 1996). Superimposition (Figure 2.8d) of the 
crystallographic structure for NS3 with that of the homology model revealed a 
difference in the folding in the region between Gly-114-Val-126 which would explain 
the importance of NS2B as the co-factor of the NS3 protein. In the homology model, the 
protein has repacked into a more rigid and stabilised conformation, particularly at the C- 
terminal domain, where more secondary structure was observed. This is contraryto the 
NS3 crystal structure of the protein when less secondary structure was observed in 
absence of the NS2B co-factor (Murthy et al., 1999). 
 
The catalytic site of a protease is crucial for the initiation of the proteolytic 
process. It is therefore the catalytic triad for HCV NS3/NS4A and DEN2 NS2B/NS3 
serine proteases were observed and found to be structurally conserved with the identical 
conformations among these catalytic triad residues.  The RMSD value found between 
the catalytic triad residues of the HCV NS3/NS4A crystal (His-57, Asp-81 and Ser-139) 
and the homology model of DEN2 NS2B/NS3 (His-51, Asp-75 and Ser-135) is 0.6, 
whilst the RMSD on the catalytic triad of the homology model of DEN2 NS2B/NS3 and 
the DEN2 NS3 crystal is 1.1.  The hydrogen bonding between the hydroxyl group of 
Ser-135 and cycloimine of the His51 side chain was observed in the catalytic triad of 
the reported DEN2 NS3 crystal structure (Figure 2.9a).  The side chain carboxyl oxygen 
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of Asp-75, however, is pointed away from His-51 (Figure 2.9a), thus caused the 
inability to form a hydrogen bond between carboxyl group of Asp-75 and cycloamine of 
His-51 that disrupt the proton transfer from Asp-75 to Ser-135 which is required to 
activate the proteolytic process.  However, in the homology model, the carboxyl oxygen 
of Asp-75 and His-51, as well as that of His-75 and the hydroxyl of Ser-135, was found 
to be at 1.6 Ǻ which is within the hydrogen bonding distance (Figure 2.9b), suggesting a 
better arrangement of catalytic residues that enables the catalytic process of the protease.     
 
The structural verifications via PROCHECK, VERIFY 3D and ERRAT for the 
generated homology model of DEN2 NS2B/NS3, HCV NS3/NS4A crystal structure and 
DEN2 NS3 crystal structure are tabulated in Table 2.1. Generally, structural verification 
from PROCHECK revealed that all the structures gave a reasonable reading of the 
Ramachandran plot, where more than 90% of non-glycine residues were located in the 
allowed region and no residues were located in disallowed. This indicated that the 
backbone of the serine protease of HCV and DEN2 have a reasonably high degree of 
homology, in spite of their low sequence identity (Brinkworth et al., 1999).  
 
Comparison of the VERIFY 3D and ERRAT analyses of the three proteins 
(crystal structure of HCV NS3/NS4A, homology model of NS2B/NS3 and crystal 
structure of DEN2 NS3), displayed a better reading in VERIFY3D and ERRAT for the 
homology model compared to that crystal structure of NS3. This seems to suggest a 
better side chain packing in the computer-generated model.  In addition, the absence of 
the NS2B co-factor in the crystal structure of NS3 is attributed to a lower quality 3d 
structure of the crystals.  This information confirmed the role of the protease co-
complexed with NS2B co-factor, which seems to re-orientate the active pocket of the 
DEN2 NS3, exhibiting a better side chain packing for a more efficient proteolytic 
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cleavage (Yusof et al., 2000).  The structural verification studies of various methods 
performed on DEN2 NS3 crystal structure showed a low confidence in the structural 
information. Thus, it is presumably not a viable template. On the other hand, structural 
verifications performed on the crystal structure of HCV NS3/NS4A showed a 
remarkably high level of confidence.  Hence, the homology model generated using 
HCV crystal structure as a template should provide a better and more accurate picture of 
the DEN2 serine protease structure. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.8: Structures of flavivirus serine proteases; a: DEN2 NS2B/NS3 complex 
homology model, b: DEN2 NS3 crystal structure, c: HCV NS3/NS4A complex crystal 
structure, d: superimposition of DEN2 NS3 crystal (green) and homology model (blue). 
Fragment that exhibiting the difference in the protein folding is shown in red. 
 
 
 
 
 
b a 
c 
d 
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Figure 2.9: Spatial arrangement of catalytic triad. In a: DEN2 NS3 crystal structure 
(pdb id: 1bef) and b:  DEN2 NS2B/NS3 complex homology model. Distance between 
the carboxyl oxygen of Asp-75 and His-51, as well as that of His75 and the hydroxyl of 
Ser-135 are indicated. 
 
 
Table 2.1: Structural verification (PROCHECK, VERIFY3D, ERRAT) and comparison 
between structure of HCV NS3/NS4A crystal, homology model of DEN2 NS2B/NS3 
and DEN2 NS3 crystal 
 
Structural Verification HCV crystal 
(1jxp) 
NS2B/NS3 homology 
model 
NS3 crystal 
(1bef) 
Ramachandran Plot    
Core 80.7 86.3 82.7 
allowed 18.0 11.0 15.1 
Generously allowed 1.3 2.7 2.2 
Disallowed 0 0 0 
VERIFY3D 97.4 90.4 52.2 
ERRAT 92.0 77.1 49.4 
 
In summary, although the overall sequence identity between DEN2 NS2B/NS3 
and HCV NS3/NS4A was only 14.8% (Brinkworth et al., 1999), the region surrounding 
the catalytic triad of the protease and the residues involved in the substrate binding 
showed a high level of sequence identity and is conserved. In addition, the information 
gathered from the results obtained from PROCHECK (all the non-glycine residue are in 
allowed region), VERIFY3D (90.4) and ERRAT (77.1) revealed the reasonable 
structure of this generated homology model that could make some plausible prediction. 
1.6Ǻ 
2.3Ǻ 
2.5Ǻ 
2.1Ǻ 
a b 
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In summary, the homology model of DEN2 NS2B/NS3 complex serine protease has 
provided information on the similarities and differences between the structures of HCV 
NS3/NS4A crystal and uncomplexed DEN2 NS3 crystal. The crystal structure of HCV 
NS3/NS4A appears to be a better choice to be used as a template in order to generate a 
model for DEN2 serine protease since results indicated better structure verification 
values for HCV NS3/NS4A than that of DEN2 NS3 crystal. This model was then used 
as the target protein (macromolecule) for the molecular docking studies of the binding 
interactions between this protein and found competitive inhibitor.  
 
2.6 Molecular Docking Studies 
2.6.1 Results 
2.6.1.1  Inhibition of bioactive compounds towards DEN2 NS2B/NS3  
 
Several competitive inhibitors towards DEN2 serine protease NS2B/NS3 
activity have been discovered through a substrate-based approach by mimicking the 
polyprotein cleavage junctions (Chanprapaph et al., 2005).  In addition, -
ketopeptidomimetic (Leung et al., 2001) compounds and guanidine derivatives (Ganesh 
et al., 2005) have also been targeted as competitive inhibitors for the DEN2 serine 
protease.  In our laboratory, the natural products, 4-hydroxpanduratin A (1) and 
panduratin A (2) as well as a synthesised compound, ethyl-3-(4-(hydroxymethyl)-2-
methoxy-5-nitrophenoxy)propanoate, (3) were found to competitively inhibit the 
activity of the DEN2 serine protease.  The structures of these compounds are shown in 
Figure 2.10.   The Kivalues for these compounds were obtained from inhibition studies 
using recombinant DEN2 NS2B/NS3 enzyme. These inhibition studies showed 4-
hydroxypanduratin A (1) to be the most potent, followed by panduratin A (2) and the 
ester (3) (Table 2.2). 
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Table 2.2: Ki values of the competitive inhibitors (Tan et al., 2006) 
Compound Ki, M 
4-hydroxy panduratin A (1) 21 
Panduratin A (2) 25 
Ester (3) 59 
 
 
Figure 2.10: Structure of the selected competitive inhibitors; (1): 4-hydroxypanduratin 
A, (2):panduratin A and (3): ethyl 3-(4-(hydroxymethyl)-2-methoxy-5-
nitrophenoxy)propanoate 
 
2.6.1.2  Active site docking 
 
These three compounds (Figure 2.10) that demonstrated competitive inhibition 
of the DEN2 serine protease were used as ligands in the binding interaction studies on 
the active site of the DEN2 serine protease.  All these ligands showed reasonably low 
internal energy, indicating that the docked conformers were in their most favourable 
conformations.  The spatial arrangement of the three ligands bound to the active site of 
DEN2 NS2B/NS3 serine protease is shown in Figure 2.11.    
 
     Docking of these compounds to the active sites showed 4-hydroxypanduratin A 
(1) to have the lowest docked energy, followed by panduratin A (2) and the ester (3) 
(Table 2.3).  These results are parallel to the Ki value observed experimentally for these 
compounds.  
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Figure 2.11: Connolly surface representations of the active site of DEN2 NS2B/NS3 
protease with the bound ligands. (a): 4-hydroxypanduratin A (1), (b): ester (3) and 
(c):panduratin A (2), which is shown in stick model. Connolly surface of the active site 
of the protease is coloured according to a charge spectrum: acidic groups are red, basic 
groups are blue and neutral groups are white. Residues labelled in black are those that 
may involve in H-bond/salt bridge interaction with ligand. Residues in labeled blue are 
involved in van der Waals interactions, while those in green are involved in both the van 
der Waals and H-bond interactions. 
 
Although panduratin A (2) showed the best free energy of binding, estimated 
inhibition constant and intermolecular energy, it has a higher ligand torsional free 
energy and internal energy values than that of 4-hydroxypanduratin A (Table 2.3).  This 
may results in a weaker binding of this ligand to the enzyme when compared to the 
4-hydroxypanduratin A (1).  The ester (3), with the most number of rotatable torsion 
points, suffer the highest torsional free energy among these three compounds and hence 
resulted in a lower binding affinity as compared to the other ligands. 
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Table 2.3: Energies (in kcal/mol) calculated using AUTODOCK 3.05 
Entry Ligand
a
  (1)  (2) (3) 
1 Estimated Free Energy of Binding
b
 -7.4 -7.7 -6.1 
2 Estimated Inhibition Constant, M (Ki) +3.9 +2.3 +33.6 
3 Final Docked Energy
c
 -10.2 -10.1 -9.2 
4 Final Intermolecular Energy -8.9 -9.6 -8.9 
5 Final Internal Energy of Ligand -1.3 -0.6 -0.3 
6 Torsional Free Energy +1.6 +1.9 +2.8 
a: three different ligands were numbered as follows: 
(1): 4-hydroxy panduratin A 
(2): Panduratin A 
(3): Ester 
b: Estimated Free Energy of Binding is derived from the Final Internal Energy (entry 4) and 
Torsional Free Energy (entry 6)  
c: Final Docked Energyis the combination of Final Internal Energy (entry 4)and Final Internal 
Energy of Ligand (entry 5) 
 
2.6.2 Discussions 
2.6.2.1 Interactions between inhibitors and residues in DEN2 NS2B/NS3 
 
Analysis was performed on the docked DEN2 NS2B/NS3 protein complex to 
establish the hydrogen bonding interactions between the ligands and the active site of 
NS2B/NS3 protease. The criteria for hydrogen bond interaction used are when the 
distance between the hydrogen and the heteroatom is within the range of 2.5-3.5 Å and 
the bond angle is between 109
o
-180
o
.  In general, these ligands exhibited hydrogen 
bonding within the active site and the residues as reported by Bazan and Fletterick 
(1989).   
 
The formation of tetrahedral intermediates of the substrates in the oxyanion hole 
is an essential part of the catalysis during proteolytic process.  This tetrahedral 
formation enables the stabilisation of the substrate which is to be cleaved by the 
protease in addition to lowering the activation energy to ease the proteolytic process. 
Oxyanion holes have been observed to interact with ligands within the active site of the 
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serine protease at the residues Gly-133 and Ser-135 by Murthy and co-workers (Murthy 
et al.,1999).  Interestingly, the carbonyl group of Gly-151 and the hydroxyl in Ser-135 
side chain were found to be involved where the plausible hydrogen bond were observed 
in all ligands studied (Table 2.4).  This seemed to suggest a different binding mode of 
the ligands to the enzyme than those observed by Murthy and his co-workers where they 
reported the residues backbone of Gly-133 and Ser-135 to be involved in forming the 
oxyanion hole.   In our study, the docked structures indicated the involvement of Gly-
133 and Ser-135 solely in the binding interactions with the ester (3) but not with the 4-
hydroxypanduratin A (1) and panduratin A (2) (Table 2.4). 
 
Figure 2.12: Hydrogen bond analysis of the docked ligands. (a): 4-Hydroxypanduratin 
A; (b): Panduratin A; (c): Ester 3. The catalytic triad residues were illustrated in ball and 
stick model, whereas other residues were depicted in stick model. The docked ligands 
were shown in thicker stick model, where the suggested hydrogen bonds were displayed 
in green dotted lines. 
(c) 
(a) (b) 
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Table 2.4: Residues in the active site of DEN2 NS2B/NS3 that are involved in  
hydrogenbonding with the various ligands 
Residues 4-Hydroxypanduratin A 
(1) 
Panduratin A 
(2) 
Ester                       
(3) 
His-51   √ 
Asp-75 √   
Ser-131   √ 
Gly-133   √  
Thr-134   √ 
Ser-135 √ √ √ 
Gly-151 √ √ √ 
Asn-152   √ 
Val-155   √ 
 
Although the involvement of the Ser-135 and Gly-151 in the formation ofthe 
oxyanion hole with all ligands was observed in the docked models, other hydrogen 
bondinginteractions were found to vary with these three ligands (Figure 2.12). Firstly, 
with the two similar ligands, 4-hydroxypanduratin A (1) and panduratin A (2), 
replacement of the hydroxyl group in the 4-hydroxypanduratin A (1) with a methoxy 
group seemed to result in a higher Kivalue observed for 4-hydroxypanduratin A (1).  
Presumably, substituting the hydroxyl group with the methoxy group in 4-
hydroxypanduratin A (1) resulted in the loss of hydrogen bonding with the carboxyl 
group in Asp-75 side chain of the DEN2 NS2B/NS3 protease.  With the ester (3), the 
high Ki value observed could be attributed to its structural flexibility.  However, this 
flexibility was somewhat compensated by additional hydrogen bonds formed between 
the ester and Ser-131, Thr-134, Asn-152 and Val-155(Table 2.4).  
 
 All three ligands were found to exhibit van der Waals interactions with Ser-131, 
Pro-132 and Try-150, suggesting the importance of these three residues as part of the 
van der Waals specificity pocket.  Likewise, His-51, Gly-133, Ser-135, Asn-152 and 
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Gly-153 may also play important roles in such binding interactions (Table 2.5). The 
small hydrophobic specificity pocket for P1 which is formed by the residues Leu-135, 
Phe-154 and Ala-157 in HCV NS3/NS4A protease (Love et al., 1996) is said to be 
equivalent to the residues Ser-131, Tyr-150 and Gly-153 in the DEN2 NS2B/NS3 
protease (Brinkworth et al., 1999). These latter residues were found to be involved in 
the van der Waals interactions with the ligands (1), (2) and (3).  This suggested more 
hydrophilic interactions of the enzyme to the ligands rather than the more hydrophobic 
interactions observed in HCV NS3/NS4A protease. In addition, Ser-131 which has been 
shown not to be an important binding residue in previous study of DEN2 NS2B/NS3 
protease (Brinkworthet al., 1999), is now observed to be involved in the van der Waals 
interaction with the ligands in our docking models (Figure 2.13). 
 
Figure 2.13: Van der Waals interactions and hydrophobic interactions between the 
docked ligands (1, 2 and 3) and the DEN2 NS2B/NS3 serine protease protein model. a: 
4-hydroxypanduratin A; b: panduratin A; and  c: ester(3) Solid surfaces in green colour 
represent the amino acid residues that were involved in Van der Waals interactions, 
whereas the solid surfaces in grey colour are the amino acid residues that were involved 
in hydrophobic interactions. Pro132 that was in yellow surface has both Van der Waals 
and hydrophobic-type of interactions. 
 
 
 
 
 
 
(a) (b) (c) 
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Table 2.5: Residues in the active site of DEN2 NS2B/NS3 that are involved in Van der 
Waals interaction 
Residues 
 
4-HydroxypanduratinA     
(1) 
Panduratin A (2) Ester (3) 
His-51 √ √  
Ser-131 √ √ √ 
Pro-132 √ √ √ 
Gly-133 √ √  
Ser-135  √ √ 
Tyr-150 √ √ √ 
Asn-152 √ √ √ 
Gly-153  √ √ 
 
Additional interactions were observed between the ligands (1) and (2) with the 
residues Val-52, Leu-128, Pro-132 and Val-155 in the hydrophobic site in the binding 
pocket of DEN2 serine protease whereby the orientation of these ligands (1) and (2) 
seemed to fit into these hydrophobic residues.  Here, the phenyl group of the hexacyclic 
portion in ligands (1) and (2) fitted into the hydrophobic pocket consisting of the residue 
Val-52, whilst the 2-methyl-2-butylene, another hydrophobic substituent of the ligands 
seemed tofit into a second hydrophobic pocket formed by the residues Leu-128, Pro-132 
and Val-155 (Figure 2.13, a and b). The ester group in ligand (3) also fitted into the 
Leu-128, Pro-132 and Val-155 hydrophobic pocket but did not interact with the residue 
Val-52 (Figure 2.13, c).  
 
Another form of interaction observed with 4-hydroxypanduratin A (1) and 
panduratin A (2) which was not observed in previous studies was the - aromatic 
interaction (Figure 2.14).  In this case, the position of the trisubstituted phenyl moiety in 
both the ligands (1) and (2) is located at about 3 - 4.2 Ǻ and is parallel to the 
pentacyclodiazo side-chain of the His-51.  This enabled a - type aromatic interaction 
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to occur.  However, such interaction was not been observed with the ester (3).  The lack 
of both the hydrophobic group that could interact with Val-52 and aromatic interaction, 
presumably, has made the ester (3) less active as observed from both its experimental 
and calculated Ki values when compared to the two ligands. 
 
Figure 2.14: Molecular orientation of the docked ligand at the catalytic triad of DEN2 
NS2B/NS3. (a): 4-hydroxypanduratin A; and (b): panduratin A. Docked ligand are 
shown in stick model, whereas catalytic triad residues are shown in ball and stick model. 
The double-ended arrow showed the suggested - type aromatic interaction between 
pentacyclodiazo side-chain of His-51 and the phenolic moiety of the ligands. 
 
In summary, several modes of interactions such as hydrogen bonding, Van der 
Waals, hydrophobic interaction as well as  interaction were observed between these 
ligands and the DEN2 NS2B/NS3 active sites.  These findings have provided further 
understanding on the binding interactions of the catalytic triad of the DEN2 NS2B/NS3 
serine protease, thus giving input into the mode of action of the catalytic triad. 
 
 
 
 
 
Asp75 
His51 
Ser135 
(a) 
Asp75 
His51 
Ser135 
(b) 
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2.6.2.2  New ligand design strategy  
 
The goal in new ligand design was to generate a new class of compounds that 
couldexhibit better binding affinity for the active site of the DEN2 NS2B/NS3 serine 
protease. For this, piperidinyl group was impregnated into the design to give a different 
class of compound from that of the active compounds found (cyclohexenyl chalcones).  
A new ligand was designed based on the model of the interaction studies between the 
active and competitively inhibiting compounds with the DEN2 NS2B/NS3 serine 
protease recombinant. The conformers with the best docked energy from their most 
populated cluster were superimposed to each other in order to construct a suitable 
pharmacophore model for a new ligand design (see Figure 2.15).  
 
Both in vitro and molecular docking studies had showed that 4-hydroxy 
panduratin A has the best binding affinity. Therefore, the new ligand should possess 
similar skeleton with this cyclohexynyl chalcone.   
 
Superimposition of the three ligands revealed the importance of the hydrophobic 
chain as exhibited by 2-methyl-2-butylene of the cyclohexynyl chalcones as well as the 
ethyl-3-ethoxypropanoate of ester (3).  Another hydrophobic interaction was attributed 
by the phenyl moiety of the both cyclohexynyl chalcones (ligands 1 and 2). This 
phenylring of the phenolic group on the cyclohexynyl chalcones not only contributed to 
the hydrophobic interactions but also seemed to be important in providing the 
stacking with the His-51.  In addition, hydrogen bonding interaction was also 
observed between the phenolic group in the cyclohexynyl chalcones and the hydroxyl 
side chain of Ser-135 in the protease.   Keeping this information in mind, introducing a 
hydrophobic long chain as well as keeping the aromatic moiety in the new ligand should 
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be strongly considered.   In addition, the position of the hydroxyl group on the aromatic 
ring should also be taken into account during the design of the new ligand. 
 
Finally, previous reports revealed the importance of generating peptide 
substrates of DEN2 NS2B/NS3 serine protease that contain dibasic amino acids due to 
the dibasic cleavage junction recognition of the binding pocket.  Hence,we intuited the 
idea of an amine functionality placement into the newly designed ligand. In this case, 
the branched methyl group from the cyclohexynyl ring of the cyclohexynyl chalcones 
was replaced by the secondary amine. In addition, introduction of different functional 
group allow us to explore the better drug candidates from different chemical spaces. 
 
Figure 2.15: Superimposition of the best docked conformer of the three competitive 
inhibitor. All hydrogens were removed for clarity. Red: 4-Hydroxypanduratin A; 
Yellow: Panduratin A; Blue: Ester (3). 
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2.6.2.3  Virtual screening of newly designed ligand 
 
      To fulfil all the required characteristics on the newly generated ligand, a 
piperidinyl class of compound as shown in Figure 2.16was constructed.  This newly 
constructed compound was screened in silico through ligand-protein docking to the 
model of DEN2 NS2B/NS3 serine protease using AUTODOCK 3.05.  
 
 
Figure 2.16: Molecule structure of the newly designed ligand 
 
      Interestingly, the docking results revealed this designed ligand to give better 
binding affinity than the three ligands (ligands 1, 2 and 3) used in constructing the 
pharmacophore model.  Its docked energy was observed to be about -11.4 kcal/mol. The 
modes of interactions such as hydrogen bonding, van der Waals and hydrophobic 
interaction were analysed and illustrated in Figure 2.17. This piperidenyl molecule (4) 
seemed to be able to disrupt the electron transfer from the carboxyl group of Asp-75 to 
Ser-135 via His-51, presumably by forming a hydrogen bond with these residues.  In 
addition, hydrogen bonding interactions were also observed between this molecule 
(4)and Gly-151 as postulated from the previous study, as well as with the Gly-133 and 
Thr-134.  These interactions possibly helped to stabilise the protein-ligand complex 
further. Van der Waals interactions were found with Pro-132 and Asn-152.  In addition, 
two hydrophobic binding interactions consisting of Val-52, as well as Pro-132, Leu-128, 
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Val-155 and Asn-152 form hydrophobic binding interactions with the molecule (4).  Pi-
pi ()stacking with His-51 was also observed with this molecule.Thus, the newly 
designed ligand (4) offers a new candidate that may open up a new chemical space of 
compounds with the binding interactions to the protease of interest.  
 
Figure 2.17: Binding interactions illustration between the newly designed ligand and 
the homology model of DEN2 NS2B/NS3 serine protease. a: Hydrogen bond were 
shown in green dotted lines; b: residues that involved in Van der Waals were shown as  
solid surfaces in green and hydrophobic interactions were solid surfaces in grey. Pro-
132 that was in yellow surface has both Van der Waals and hydrophobic-type of 
interactions. 
 
 
 
(a) (b) 
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CHAPTER 3 
SYNTHESIS OF THE DESIGNED MOLECULE 
 
3.1 Retrosynthetic Analysis 
 
The newly designed ligand (4) predicted a good binding interaction with the 
DEN2 NS2B/NS3 serine protease model.  Thus, as part of the project, the molecule (4) 
was synthesised for in vitro screening in order to validate the pharmacophoric model 
that was constructed.  The molecule (4) shares a similar skeleton to Panduratin A.  
However, it falls into piperidinyl class of compound instead of the cyclohexynyl 
chalcones of 4-hydroxypanduratin A (1) and panduratin A (2). The molecule was 
disconnected into 4 different moieties (Scheme 3.1) in the retrosynthetic analysis.  
 
From our retrosynthesis, nicotinic acid was chosen to be the starting material for 
the synthesis since it is cheap and available in abundant. Making an ethyl ester to mask 
the carboxylic acid group in the nicotinic acid, incorporation of the moiety C into the 
nicotinic acid (D) through 1,4-nucleophilic addition should be possible following the 
pyridinyl ring activation by chloroformate. The α,β-unsaturated ethyl ester (E) 
generated from the dihydropyridine synthesis could then be subjected to Michael 
addition with the moiety B to give the ester (F).  Finally, hydrogenation of the 
unsaturated bond would form the piperidine (G) which was then converted to the 
Weinreb amide (H).  Grignard reaction between the moiety B and the Weinreb amide 
(H) should give the carbamate (I).  The deprotection of the carbamate (I) followed by 
methylenedioxy ring opening should furnish the targeted product (4).  
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Scheme 3.1: Retrosynthesis analysis of the targeted compound 
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In summary, there are 3 key steps involved in this strategy to connect all 4 
moieties, starting from a tandem piperidinyl ring activation and 1,4-nucleophilic 
addition, followed by Michael 1,4-addition, and finally ketone synthesis from Weinreb 
amide. The background of these key steps syntheses will be discussed. 
 
3.2 Chemistry of Pyridinyl, Dihydropyridinyl and Piperidinyl Ring Synthesis: 
Synthesis of Dihydropyridines 
 
 The chemistry of dihydropyridines began with Hantzsch in 1882 when he 
performed the reaction to synthesise dihydropyridines (the Hantzsch reaction) as 
antihypertensive drugs (Hantzsch, 1882).   The dihydropyridines was formed through 
the condensation reaction between 2 moles of ethyl acetoacetate and 1 mole of 
aldehyde-ammonia under warm ethanol to give a good yield (Eisner and Kuthan, 1972) 
(Scheme 3.2).  
 
 
Scheme 3.2: Hantzsch dihydropyridine synthesis 
 
Later, many syntheses of dihydropyridine were carried out based on this reaction 
by substituting different acetoesters, aldehydes and the ammonia species to make 
various kind of dihydropyridine of interests (Stout and Meyers, 1982).  However, only 
the symmetrical dihydropyridines can be obtained based on this method. 
 
 Various approaches to synthesise dihydropyridine, particularly the asymmetrical 
and or, functionalised 1, 4-dihydropyridine, apart from Hantzsch reaction, have been 
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reported.  This included many reactions such as rearrangement, fragmentation 
cycloaddition and insertion reactions, which were reviewed by Stout and Meyers, in 
1982 (Stout and Meyers, 1982).    More recently, Lavilla updated the development of 
dihydropyridine synthesis in his review.  One of the reviewed methods that attracted the 
attention is the nucleophilic addition to the pyridinium salt to make multifunctional 
dihydropyridine. Here, two kinds of pyridinium salt that were highlighted, the N-
alkylpyridinium salt and N-acylpyridinium salt.  The nuleophilic addition of various 
nucleophile to the N-alkylpyridinium salt that were generated in situ afforded 
dihydropyridine in good yield, making this method a good choice for natural product 
synthesis, particularly in total syntheses of alkaloids.  Nevertheless, the generation N-
acylpyridinium salt from more reactive electrophilic species are possible.  The more 
reactive N-acylpyridinium is generated in situ and reacts readily with wide range of 
nucleophile species to afford various dihydropyridine with high degree of regio- and 
stereoselectivity (Lavilla, 2002).  Due to the well-developed chemistry, this method of 
dihydropyridine generation is adopted for this work.   
 
Hilgeroth and co-workers, in their synthesis of 6,12-diazatetrakishomocubanes 
and 3,9-diazatetraasteranes used various multi-functioned 1,4-dihyropyridines 
(Hilgeroth and Baumeister, 2000; Hilgeroth et al., 2002) as the starting material.  
Hilgeroth syntheses of cubanes began with the formation of 1,4-dihydropyridine as 
shown below (Scheme 3.3). 
 
Scheme 3.3: Hilgeroth’s synthesis of dihydropyridine as the precursor of cubanes 
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3.3 1, 4-Michael Addition 
 
 Michael addition typically refers to the base-promoted nucleophilic addition of 
the nucleophile (or termed as Michael donor) to an α,β-unsaturated substrates (or 
Michael acceptor) that contains carbonyl functionality, such as esters, aldehydes, 
ketones and amides (Bergman et al., 1959).  The development of Michael addition has 
grown tremendously with various forms of Michael donors and acceptors and has 
widened the scope of the organic reaction that can be classified as Michael addition.  
 
 However, to date, there are few publications on Michael addition reaction on 
α,β-unsaturated ester with dihydropyridine as the Michael acceptor. The closest related 
work is on the conjugate addition is on the Michael acceptor, 3-alkoxycarbonyl-
dihydropyridones which is in the synthesis of inhibitors of 2,3-oxidosqualene-lanosterol 
cyclase by Dodd and his co-workers (Scheme 3.4).  Here, the conjugate addition was 
the key step in incorporating a medium-sized alkyl chain to the 3-alkoxycarbonyl-
dihydropyridones, followed by several functional groups conversions to furnish some 2-
alkylpiperindin-4-ol as the final product (Dodd and Oehlschlager, 1992).  Starting from 
the model study reaction by using higher order cuprates generated from 2 equivalents of 
n-BuLi and 1 equivalent of CuCN at -78oC as the Michael donor that gave a reasonable 
good yield (87-91%), they used the squalene-type of alkyl chain and thienyl 
cyanocuprate to generate the Michael donor species to give the Michael adduct was in 
excellent yield (90%) (Dodd and Oehlschlager, 1992). 
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Scheme 3.4: Synthesis of inhibitors of 2,3-oxidosqualene-lanosterol cycliase using 1,4-
Michael addition as a key step  
 
The Michael donors that are of interest are the organometallic reagent, due to the 
ease of generation. There are varieties of organometallic reagents such as organozinc, 
organomagnesium, organolithium and organocopper that could be used as good Michael 
donors.  Typically, cuprates reagent, or Gilman reagent that is generated from the 
organolithium and copper (I) salt are among the most popular method employed in 
many 1,4-additions due to its good regioselectivity.   
 
Since the extensive research and development were done on the Michael 
addition on α, β-unsaturated carbonyl species, which resulted many publications and 
reviews, utilisation of the 1,4-Michael addition may be possible to connect another 
moiety into the molecule, after the α, β-unsaturated ester was formed form the 1,4-
dihydropyridine generated from nucleophilic addition to acylpyridinium salt (Scheme 
3.5).  
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Scheme 3.5: Proposed reaction using 1,4-Michael addition as the key step to 
incorporate the butyl moiety to the dihydropyridine 
 
3.4 Weinreb Amide  
  
 Since the work was pioneered by Nahm and Weinreb, the use of N-methoxy-N-
methylamides in the synthesis of ketone derivatives, this Weinreb amide has rapidly 
popularised itself in organic synthesis. Nahm and Weinreb found N-methoxy-N-
methylamides to react cleanly with Grignard and organolithium reagents to form 
ketones in a one-pot reaction (Scheme 3.6) (Nahm and Weinreb, 1981). 
 
Scheme 3.6: General example of ketone synthesis from Weinreb amide using Grignard 
reagent 
 
Unlike other nucleophilic attack on carbonyl functionalities that usually give rise 
to the secondary and tertiary alcohol as the adduct, the Weinreb amide is always utilised 
to make ketones in the organic synthesis, because of the ease of preparation with only a 
small amount of side-reactions during the nucleophilic addition and mild, selective 
acidic workup. These advantages can be attributed to the stability of the tetrahedral 
metal-chelated intermediate which is formed by addition of nucleophiles to N-methoxy-
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N-methylamides which reduced the propensity of producing a secondary or tertiary 
alcohol by an over reactive Grignard and/or organolithium reagents to the substrate. In 
addition, reactions between organometallic reagents and the Weinreb amides generally 
give good-to-excellent yields under fairly mild conditions (at -78oC or 0oC, and solvents 
such as THF, ether or DME). (Mentzel and Hoffmann, 1997) 
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3.5 Materials and Methods 
3.5.1 Materials and instruments used  
 
The chemicals used in this synthesis were purchased from Merck and Sigma Aldrich. 
NMR spectra were recorded from the following instruments: JEOL ECA 400, JEOL 
Lambda 400.  Thin layer chromatography (TLC) was conducted on silica gel F
254 
TLC 
plates purchased from Merck. Flash column chromatography was carried out using 
silica gel (40 to 63 µm) purchased from Merck and Mallinckrodt. Diethyl ether (Et
2
O), 
tetrahydrofuran (THF) were distilled from sodium-benzophenone prior to use, 
Dichloromethane (CH2Cl2) were distilled from CaH2 prior to use. All the air-sensitive 
reactions were performed under nitrogen, with the related glasswares were heat-dried 
under high vacuum using hot air gun as a heating source. Table 3.1 illustrates the 
molecules involved in the synthesis work. 
 
Table 3.1: List of molecules that were used and synthesised in this work 
No. Molecular structure Name of the molecule 
1 
 
Nicotinic acid 
2 
 
Ethyl Nicotinate 
3 
 
Diethyl-4-phenylpyridine-1,3(4H)-dicarboxylate 
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4 
 
Ethyl (1-phenoxycarbonyl-4-phenylpyridinyl)-
3(4H)-carboxylate  
5 
 
Ethyl (1-tert-butoxycarbonyl-4-phenylpyridinyl)-
3(4H)-carboxylate 
6 
 
Ethyl (1-tert-butoxycarbonyl-2-butyl-4-phenyl)-
3,4-dihydropyridinyl-3-carboxylate  
7 
 
Ethyl (1-tert-butoxycarbonyl-2-butyl-4-phenyl)-
piperidinyl-3-carboxylate 
8 
 
(1-tert-butoxycarbonyl-2-butyl-4-phenyl)-
piperidinyl-3-carboxylic acid 
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9 
 
1-tert-butoxycarbonyl-2-butyl-3-
(methoxy(methyl)carbamoyl)-4-phenylpiperidine 
10 
 
1-tert-butoxycarbonyl-2-butyl-3-(benzo-1,3-
dioxol-4-carbonyl)-4-phenylpiperidine 
11 
 
1-tert-butoxycarbonyl-2-butyl-3-hydroxymethyl-
4-phenylpiperidine 
12 
 
1-tert-butoxcarbonyl-2-butyl-3-formyl-4-
phenylpiperidine 
13 
 
1-tert-butoxycarbonyl-3-(benzo-1,3-dioxol-4-
carbonyl)-2-butyl-4-phenylpiperidine 
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14 
 
(2-butyl-4-phenylpiperidin-3-yl)(2,3-
dihydroxyphenyl)methanone 
 
3.5.2 Synthesis of Ethyl Nicotinate (2) 
 
37.02 g of nicotinic acid 1(300.7 mmol) was refluxed together with 115 cm3 of EtOH 
absolute and 50 cm3 of H2SO4 for 4 hours in oil bath at 135 
oC. Reaction mixture was 
then cooled in ice bath, followed by addition 25% NH3 aqueous until slightly alkaline, 
and evaporated to remove excessive EtOH. The pale yellow oil formed was then 
extracted with Et2O followed by washing with brine. 82% yield was obtained as pale 
yellow oil. 1H NMR (400MHz, CDCl3): 1.41 (t, 3H, J=7.2Hz, H1’), 4.41 (q, 2H, 
J=7.2Hz, H2’), 7.39 (q, 1H, J=4.8Hz, H5), 8.29 (dt, 1H, J=4.8Hz, 2.1Hz, H4), 8.76 (dd, 
1H, J=2.1Hz, 4.8Hz, H6), 9.22 (s, 1H, H2). (Sambrook et al., 2005) 
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3.5.3 Synthesis of diethyl 4-phenylpyridine-1,3(4H)-dicarboxylate (3) 
 
Ethyl nicotinate 2 (3.32 g, 22.0 mmol) was dissolved in anhydrous THF (200 cm3) and 
cooled to -10oC. Ethyl chloroformate (2.38 g, 22.0 mmol) was then added dropwise and 
stirred for 30 minutes. The reaction mixture was then added catalytic amount of copper 
(I) iodide (0.22 g, 1.29 mmol) followed by 12.0 cm3 PhMgCl (2 M in THF). Reaction 
mixture was then stirred at room temperature for additional 2 hours. The reaction 
mixture was then quenched by ammonium chloride, vacuumed dry to remove THF. The 
remaining aqueous layer was then extracted with Et2O, followed by washing of organic 
layer with NH3 (20%):NH4Cl = 1:1, H2O, 10% HCl, H2O, brine. The solvent was then 
evaporated to dryness and recrystallized with MeOH to give 69% yield as white 
powder. 1H NMR (400MHz, CDCl3): 1.16 (t, 3H, J=7.1Hz, H1’), 1.38 (t, 3H, J=6.8, 
H1”), 4.08 (m, 2H, H2’), 4.36 (q, 2H, J=7.2Hz, H2”), 4.47 (d, 1H, J=4.8Hz, H4), 5.17 
(brs, 1H, H5), 6.88 (brd, 1H, H6), 7.26 (m, 5H, H Phenyl), 8.07 (brs, 1H, H2). 
(Hilgeroth and Baumeister, 2000)  
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3.5.4 Synthesis of ethyl (1-phenoxycarbonyl-4-phenylpyridinyl)-3(4H)-
carboxylate (4) 
N
O
O
O O
2
3
4
5
6
1'
2'
 
Ethyl nicotinate 2 (3.32g, 22.0 mmol) was dissolved in anhydrous THF (200 cm3) and 
cooled to -10oC. Phenyl chloroformate (3.44g, 22.0 mmol) was then added dropwise 
and stirred for 30 minutes. The reaction mixture was then added catalytic amount of 
copper(I) iodide (0.246 g, 1.29 mmol) followed by 13.01 cm3 PhMgCl (1.69 M in THF). 
Reaction mixture was then stirred at room temperature for additional 2 hours. The 
reaction mixture was then quenched by ammonium chloride, vacuumed dry to remove 
THF. The remaining aqueous layer was then extracted with Et2O, followed by washing 
of organic layer with NH3 (20%):NH4Cl=1:1, H2O, 10% HCl, H2O, brine. The solvent 
was then evaporated to dryness and recrystallized with MeOH to give 62% yield as 
white powder. 1H NMR (400MHz, CDCl3): 1.19 (t, 3H, J=7.1Hz, H1’), 4.13 (m, 2H, 
H2’), 4.50 (d, 1H, J=4.4Hz, H4), 5.30 (brs, 1H, H5), 7.03 (brd, 1H, J=5.4Hz, H6), 7.31 
(m, 10H, H Phenyl), 8.22 (brs, 1H, H2). 13C NMR (100MHz, CDCl3): 14.05, 38.08, 
60.39, 113.22, 120.46, 121.32, 126.31, 126.82, 128.08, 128.49, 129.56, 131.51, 144.69, 
149.68, 150.58, 166.27. 
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3.5.5 Synthesis of ethyl (1-tert-butoxycarbonyl-4-phenylpyridinyl)-3(4H)-
carboxylate (5) 
 
Product 4 (2.37 g, 6.78 mmol) was dissolved in anhydrous THF and cooled to -42 oC. In 
another flask, t-BuOK (1.53g, 13.6 mmol) was dissolved in 30 cm3 of anhydrous THF 
(5 cm3 for rinsing purposes), then cannulated to substrate dropwise. Reaction mixture 
was then stirred for 30 minutes, quenched with H2O, followed by extraction with 3 
times of Et2O. The extracted product was washed with NH3 (20%):NH4Cl=1:1, H2O, 
then H2O, brine, followed by Na2SO4 treatment then rotadry. The crude wash purified 
from flash column chromatography using petroleum ether and EtOAc as eluting solvent. 
1H NMR (400MHz, CDCl3): 1.12 (t, 3H, J=7.0Hz, H1’), 1.53 (s, 9H, H1”), 4.03 (m, 2H, 
H2’), 4.43 (d, 1H, J=4.0Hz, H4), 5.08 (brs, 1H, H5), 6.80 (brs, 1H, H6), 7.20 (m, 5H, H 
Phenyl), 8.02 (brd, 1H, H2). 13C NMR (100MHz, CDCl3): 14.03, 28.04, 38.94, 60.07, 
83.60, 110.95, 111.75, 120.65, 126.52, 126.56, 128.00, 128.33, 132.16, 145.39, 149.64, 
166.68. 
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3.5.6 Synthesis of ethyl (1-tert-butoxycarbonyl-2-butyl-4-phenyl)-3,4-dihydro 
pyridinyl-3-carboxylate (6) 
 
In anhydrous condition, 2 equivalents of n-BuLi (1.6 M in hexanes, 12.2 ml) was added 
dropwise into a cooled (-40 oC to -50 oC) CuCN (0.875 g, 9.77 mmol) in 100 ml THF 
and stirred for 30 minutes under cold bath. The resulting 2 immiscible layers, where 
cuprate was formed at the lower layer as pale yellow coloured solution was then cooled 
to -78 oC and the resulting solution (86.7 ml) was cannulated into the substrate 5 (2.79g, 
8.47 mmol) at this temperature. The reaction was quenched with NH4Cl saturated 
solution, extracted with Et2O, followed by washing with more NH4Cl, then water and 
brine, finally dried with Na2SO4 anhydrous. Further purification was performed using 
flash column chromatography using petroleum ether and EtOAc as eluting solvent. The 
product was purified as a mixture of enantiomer with 31% yield. 1H NMR (400MHz, 
CDCl3): 0.81 (m, 3H, H1’”), 1.05 (t, 3H, J=7.2Hz, H1’), 1.28 (m, 6H, H2’”, H3’”, 
H4”’), 1.46 (s, 9H, H1”), 2.81 (dd, 1H, J=62.7Hz, 3.8Hz, H3), 3.73 (brd, 1H, J=11.6Hz, 
H4), 3.94 (m, 2H, H2’), 4.55 (brd, 1H, J=10.8Hz, H2), 4.72 (brd, 1H, J=8.4Hz, H5), 
6.76 (d, 1H, J=7.6Hz, H6), 7.14 (m, 5H, H Phenyl). 13C NMR (100MHz, CDCl3): 
13.95, 22.55, 27.96, 28.21, 37.98, 50.65, 51.14, 51.58, 52.94, 60.51, 81.04, 109.41, 
122.92, 123.16, 126.63, 128.30, 142.96, 152.20, 171.72. LRMS (EI): m/z 387 (M+, 1), 
214 (65), 156 (100), 69 (77), 41 (91). HRMS (EI) calculated for C23H33O4N (M+): 
387.2410, found 387.2403. 
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3.5.7 Synthesis of ethyl (1-tert-butoxycarbonyl-2-butyl-4-phenyl)-piperidinyl-3-
carboxylate (7) 
 
The reaction flask was charged with substrate 6 (0.107g, 0.277 mmol) and Pd/C catalyst 
(0.029g, 0.0277 mmol Pd). 10 ml of MeOH was added and then the mixture was purged 
with nitrogen gas to remove oxygen. The reaction began when it was then purged with 
hydrogen and stirred under hydrogen at room temperature. The completion of reaction 
was monitored by TLC. After completion of reaction, the reaction mixture was again 
purged with nitrogen and the catalyst was then filtered off. The product was obtained 
for 99% yield after the solvent was evaporated off. 1H NMR (400MHz, CDCl3): 0.82 
(m, 3H, H1’”), 0.96 (m, 3H, H1’), 1.17 (m, 6H, H2’”, H3’”,H4”’), 1.44 (s, 9H, H1”), 
1.71 (m, 1H, H5), 1.81 (m, 1H, H5), 2.81 (m, 1H, H6), 2.94 (dt, 1H, J=12.4Hz, 4.8Hz, 
H3), 3.11 (m, 1H, H4), 3.88 (m, 2H, H2’), 3.95 (brd, 1H, J=13.2Hz, H6), 4.62 (dd, 1H, 
J=79.1Hz, 10.0Hz, H2), 7.15 (m, 5H, H Phenyl). 13C NMR (100MHz, CDCl3): 13.84, 
22.45, 25.6, 27.70, 28.40, 33.63, 37.19, 38.36, 42.76, 50.62, 51.99, 57.65, 79.73, 
126.68, 127.31, 128.32, 144.13, 154.82, 209.88. LRMS (EI): m/z 389 (M+, 5), 276 (80), 
232 (100), 128 (21), 84 (17), 57 (57). HRMS (EI) calculated for C23H35O4N (M+): 
389.2566, found 389.2559. 
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3.5.8 Synthesis of (1-tert-butoxycarbonyl-2-butyl-4-phenyl)-piperidinyl-3-
carboxylic acid (8) 
 
The substrare 7 was dissolved in little amount of THF, then 2M KOH solution in EtOH 
95% was added. The mixture was then refluxed. The mixture was acidified with 2M 
HCl and extracted with EtOAc. The combined extracted product was then washed with 
water brine then dried with Na2SO4 anhydrous, followed by evaporation of the solvent 
to get the product in quantitative yield. 1H NMR (400MHz, CDCl3): 0.82 (m, 3H, H1’”), 
1.20 (m, 6H, H2’”, H3’”, H4’”), 1.41 (s, 9H, H1”), 1.66 (brd, 1H, J=13.2Hz, H5), 1.77 
(m, 1H, H5), 2.72 (m, 1H, H6), 2.95 (dt, 1H, J=12.2Hz, 4.8Hz, H3), 3.04 (m, 1H, H4), 
3.95 (dd, 1H, J=64.3Hz, 11.2Hz, H6), 4.60 (dd, 1H, J=71.9Hz, 13.2Hz, H2), 7.09 (m, 
5H, H Phenyl). 13C NMR (100MHz, CDCl3): 14.00, 22.33, 26.11, 27.80, 28.40, 29.67, 
33.73, 37.91, 50.73, 52.35, 80.15, 126.51, 127.23, 128.40, 143.79, 154.83, 176.51. 
LRMS (EI): m/z 361 (M+, 5), 304 (22), 260 (29), 204 (38), 57 (100). HRMS (EI) 
calculated for C21H35O4N (M+): 361.2253, found: 361.2242. 
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3.5.9 Synthesis of 1-tert-butoxycarbonyl-2-butyl-3-(methoxy(methyl)carbamoyl)-
4-phenylpiperidine (9) 
 
The substrate 8 was dissolved in CH2Cl2. DMAP and PyBrOP were then added and 
stirred for 1 hour. NHMe(OMe).HCl was then added and strirred for 19 hours at room 
temperature. The reaction mixture was quenched by adding water, extracted by CH2Cl2 
and the organic layer was washed with brine. Purification of the crude through column 
chromatography (hex:EtOAc= 3:17) afforded 49% of the product. 1H NMR (400MHz, 
CDCl3): 0.81 (m, 3H, H1’”), 1.22 (m, 4H, H2’”, H3’”), 1.42 (s, 9H, H1”), 1.58 (m, 2H, 
H4’”), 1.80 (m, 2H, H5), 2.84 (m, 1H, H6), 2.92 (s, 3H, H1’), 3.30 (m, 2H, H3, H4), 
3.62 (s, 3H, H2’), 3.99 (dd, 2H, J=72.3Hz, 13.6Hz, H6), 4.60 (brd, 1H, J=43.16Hz, H2 
), 7.13 (m, 5H, H Phenyl). 13C NMR (100MHz, CDCl3): 13.84, 22.10, 25.61, 27.64, 
28.25, 31.84, 33.76, 36.93, 38.40, 47.22, 50.91, 61.49, 79.23, 125.99, 127.09, 128.03, 
144.08, 154.51, 172.18. LRMS (EI): m/z 404 (M+, 1), 303 (24), 273 (40), 247 (43), 57 
(100). HRMS (EI) calculated for C23H36O4N2 (M+): 404.2675, found 404.2682. 
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3.5.10 Synthesis of 1-tert-butoxycarbonyl-2-butyl-3-(benzo-1,3-dioxol-4-carbonyl)-
4-phenylpiperidine (10) 
 
a. from 9 
The Grignard of 4-Bromo-1,3-benzodioxole was prepared in prior to use by gently 
reflux it with magnesium turnings in THF for about 1 hour. 1.1 eqv. of TMEDA was 
then added to the Grignard reagent and stirred for 1 hour at room temperature. In the 
other pot, substrate 9 was dissolved in THF and transferred to the Grignard reagent. The 
mixture was stirred at room temperature for 1 1/2 hour, followed by quenching with 
saturated NH4Cl, extraction with Et2O, and dried with anhydrous MgSO4. Purification 
of the crude through column chromatography (Hex: EtOAc = 19:1 to 9:1) afforded 7.8 
% of product. 
 
b. from 13 
Substrate 13 (0.042g, 0.090 mmol) was dissolved in CH2Cl2, and 1.1 eqv. of DMP 
(0.03ml, 0.3 M in CH2Cl2) was added and stirred at room temperature for 1 hour. 20% 
Na2S2O3 in saturated Na2CO3 was then added into the reaction mixture and the reaction 
mixture was diluted with Et2O. Extraction was performed with Et2O, followed by 
treatment with anhydrous MgSO4. Evaporation of the solvent afforded the pure product 
in quantitative yield without further purifications. 1H NMR (400MHz, CDCl3): 0.74 (m, 
3H, H1”’), 1.04 (m, 4H, H2”’, H3”’), 1.42(s, 9H, H1”), 1.58 (m, 2H, H4”’), 1.80 (m, 
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2H, H5), 2.84 (m, 1H, H6), 3.40 (dt, 1H, J=11.9, 3.6Hz, H4), 4.01(dd, 1H, J=79.7Hz, 
13.4Hz, H6), 4.05 (m, 1H, H3), 4.77 (dd, 1H, J=72.4, 12.7Hz, H2), 6.05 (d, 2H, 
J=3.2Hz, H4’), 6.75 (dd, 1H, J=16.8Hz, 8.1Hz, H2’), 6.88 (dd, 1H, J=15.9Hz, 7.6Hz, 
H1’), 7.03 (m, 1H, H3’), 7.16 (m, 5H). 13C NMR (100MHz, CDCl3): 13.98, 22.29, 
25.82, 27.55, 28.60, 29.68, 34.12, 38.25, 50.73, 51.71, 55.63, 79.43, 101.46, 112.42, 
119.42, 121.31, 126.14, 127.31, 128.35, 144.56, 147.27, 148.47, 154.61, 196.54. LRMS 
(EI): m/z 465 (M+, 5), 408 (22), 364 (55), 244 (68), 57 (100). HRMS (EI) calculated for 
C28H35O5N1 (M+): 465.2515, found 465.2527. 
 
3.5.11 Synthesis of 1-tert-butoxycarbonyl-2-butyl-3-hydroxymethyl-4-phenyl 
piperidine (11) 
 
Under anhydrous and nitrogen condition, substrate 7 was dissolved in THF and cooled 
to -78oC. 3 eqv. of LiAlH4 (2M solution in THF) was added dropwise and reaction 
mixture was stirred for 1 hour by slowly heated up to room temperature. Reaction flask 
was then placed into cold bath, quenched by slow addition of MeOH into the reaction 
mixture, diluted with water, followed by 10% NaOH. Extraction was done with Et2O 
and the extract was dried with anhydrous MgSO4. The extract was then evaporated to 
afford quantitative pure product without further purification. 1H NMR (400MHz, 
CDCl3): 0.84 (m, 3H, H1”’), 1.19 (m, 6H, H2”’, H3”’, H4”’), 1.42 (s, 9H, H1”), 1.65 
(m, 2H, H5), 2.06 (m, 1H, H3), 2.60 (m, 1H, H4), 2.80 (m, 1H, H6), 3.25 (m, 2H, H1’), 
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4.02 (dd, 1H, J=75.9Hz, 13.2Hz, H6), 4.48 (dd, 1H, J=59.9Hz, 12.0Hz, H2), 7.15 (m, 
5H). 13C NMR (100MHz, CDCl3): 14.16, 22.68, 24.23, 28.47, 34.46, 37.38, 38.78, 
40.72, 46.76, 51.62, 62.89, 79.37, 126.67, 127.20, 128.70, 143.80, 155.10. LRMS (EI): 
m/z 347 (M+, 1), 290 (20), 234 (100), 204 (18), 190 (42), 57 (55). HRMS (EI) 
calculated for C21H33O3N1 (M+): 347.2460, found 347.2466. 
 
3.5.12 Synthesis of 1-tert-butoxycarbonyl-2-butyl-3-formyl-4-phenylpiperidine 
(12) 
 
a. from 9 
Under anhydrous and nitrogen condition, substrate 9 was dissolved in THF and cooled 
to 0oC. 3 eqv. of LiAlH4 (2M solution in THF) was added drop wise and reaction 
mixture was stirred at 0oC for 1 hour. Reaction was then quenched by slow addition of 
MeOH into the reaction mixture, diluted with water, followed by 10% NaOH. 
Extraction was done with Et2O and the extract was dried with anhydrous magnesium 
sulphate. The extract was then evaporated to afford 91.1% of pure product without 
further purification. 
 
b. from 11 
Substrate 11 was dissolved in CH2Cl2, and 1.1 eqv. of DMP (0.3 M in CH2Cl2) was 
added and stirred at room temperature for 1 hour. 20% Na2S2O3 in saturated Na2CO3 
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was then added into the reaction mixture and the reaction mixture was diluted with 
Et2O. Extraction was performed with Et2O, followed by treatment with anhydrous 
MgSO4. Evaporation of the solvent afforded the pure product in 87.7% yield without 
further purifications. 1H NMR (400MHz, CDCl3): 0.82 (m, 3H, H1”’), 1.18 (m, 6H, 
H2”’, H3”’, H4”’), 1.43 (s, 9H, H1”), 1.86 (m, 2H, H5), 2.82 (m, 1H, H3), 2.95 (m, 1H, 
H6), 3.19 (m, 1H, H4), 4.05 (dd, 1H, J=84.7Hz, 12.0Hz, H6), 4.71 (dd, 1H, J=92.3Hz, 
9.6Hz, H2), 7.22 (m, 5H, H Phenyl), 9.39 (d, 1H, J=15.6Hz, H1’). 13C NMR (100MHz, 
CDCl3): 13.97, 22.35, 26.64, 27.63, 28.39, 29.65, 34.01, 37.22, 51.70, 56.84, 80.12, 
126.98, 127.46, 128.84, 142.51, 154.67, 203.10. LRMS (EI): m/z 345 (M+, 1), 288 (26), 
244 (45), 217(43), 57 (100). HRMS (EI) calculated for C21H31O3N1 (M+): 345.2304, 
found 345.2314. 
 
3.5.13 Synthesis of 1-tert-butoxycarbonyl-3-(benzo-1,3-dioxol-4-carbonyl)-2-butyl-
4-phenylpiperidine (13) 
 
The Grignard of 4-bromo-1,3-benzodioxole was prepared in prior to use by gently 
reflux it with magnesium turnings in THF for about 1 hour. In another flask, was 
charged with substrate 12 and dissolved in THF, then added into the Grignard reagent 
and stirred at room temperature for 2 hours. Reaction mixture was then quenched with 
saturated NH4Cl, extracted with Et2O, dried with anhydrous MgSO4. Purification of the 
crude product from column chromatography (hex:EtOAc = 19:1 to 4:1) afforded 58.4 % 
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of product. 1H NMR (400MHz, CDCl3): 0.78 (t, 3H, J=7.0Hz, H1”’), 1.19 (m, 4H, 
H2”’, H3”’), 1.24 (s, 9H, H1”), 1.56 (m, 2H, H4”’), 1.69 (m, 2H, H5), 2.36 (m, 1H, 
H3), 2.82 (m, 1H, H6), 3.12 (m, 1H, H4), 3.86 (m, 1H, H2), 4.02 (dd, 1H, J=14.4Hz, 
4.4Hz, H2), 4.61 (s, 1H, H5’), 5.85 (d, 2H, J=34.0Hz, H4’), 6.64 (d, 1H, J=7.6Hz, H1’), 
6.73 (t, 1H, J=7.8Hz, H2’), 6.83 (d, 1H, J=8.0Hz, H3’), 7.19 (m, 5H, H Phenyl). 13C 
NMR (100MHz, CDCl3): 14.16, 22.25, 25.98, 27.94, 228.25, 35.13, 37.35, 39.64, 48.34, 
51.99, 68.15, 78.91, 100.63, 107.19, 118.74, 121.46, 124.88, 126.54, 127.72, 128.63, 
142.69, 143.90, 146.81, 154.92. LRMS (EI): m/z 467 (M+, 1), 410 (24), 366 (28), 247 
(56), 57 (100). HRMS (EI) calculated for C28H37O5N1 (M+): 467.2672, found 467.2671. 
 
3.5.14 Synthesis of (2-butyl-4-phenylpiperidin-3-yl)(2,3-dihydroxyphenyl) 
methanone (14) 
 
Substrate 13 was dissolved in anhydrous CH2Cl2 and cooled to -78 oC. 5 eqv. of BCl3 
(1M in hexanes) was then added dropwise and the reaction mixture was stirred at -78oC 
for 2 hours, then heated up slowly and stirred at room temperature for additional 24 
hours under nitrogen. MeOH was then added and stirred overnight. Reaction mixture 
was then evaporated and purified by column chromatography (100% CH2Cl2 to CH2Cl2: 
MeOH = 9:1) to afford 81.7 % of product. 1H NMR (400MHz, CDCl3): 0.71 (t, 3H, 
J=7.2Hz, H1”’), 1.19 (m, 4H, H2”’, H3”’), 1.56 (m, 1H, H4”’), 1.82 (m, 1H, H4”’), 
2.05 (m, 1H, H5), 2.29 (m, 1H, H5), 3.23 (m, 1H, H6), 3.44 (m, 1H, H4), 3.72 (m, 1H, 
H6), 4.15 (m, 1H, H2), 4.79 (m, 1H, H3), 6.85 (t, 1H, J=8.0Hz, H5’), 7.01 (d, 1H, 
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J=8.0Hz, H4’), 7.08 (t, 1H, J=7.2Hz, H Phenyl), 7.15 (d, 2H, J=7.4Hz, H Phenyl), 7.22 
(t, 2H, J=9.0Hz, H Phenyl), 7.69 (d, 1H, J=8.0Hz, H6’), 8.05 (brs, 1H, 3’OH), 8.95 (brs, 
1H, H1”), 11.94 (s, 1H, 2”OH). 13C NMR (100MHz, CDCl3): 13.57, 22.18, 25.81, 
27.96, 29.45, 29.69, 36.81, 39.80, 48.12, 54.75, 118.52, 120.50, 121.21, 121.56, 127.22, 
128.87, 141.32, 145.34, 149.81, 203.78. LRMS (EI): m/z 353 (M+, 1), 303 (24), 273 
(40), 247 (43), 57 (100). HRMS (EI) calculated for C22H27O3N1 (M+): 353.1991, found 
353.1992. 
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3.6 Results and Discussions 
3.6.1 Synthesis setup for the designed ligand: (2-butyl-4-phenylpiperidin-3-
yl)(2,3-dihydroxyphenyl)methanone  
 
Scheme 3.7: Structure of the target compound  
 
The synthesis of the target compound (shown in Scheme 3.7) began with 
esterification of the starting material, nicotinic acid, in the presence of sulfuric acid in 
ethanol. The esterification of the nicotinic acid was performed in order to mask the 
carboxylic acid from interfering in a later step involving a 1,4-nucleophilic addition on 
the pyridinyl ring using organomagnesium reagent. Similar reaction conditions and 
workup protocols were used by Sambrook and co-worker in their work on heterocyclic 
molecule construction (Sambrook et al., 2005). Refluxing the reaction mixture for 4 
hour, followed by treatment with ammonia aqueous, gave a reasonably good yield of 82 
% (Scheme 3.8). 
  
Scheme 3.8: Esterification of nicotinic acid 
 
Following the procedure of Hilgeroth and Baumeister (Hilgeroth and 
Baumeister, 2000), the ester was first reacted with ethyl chloroformate to form the 
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carbamate intermediate which was subsequently reacted with phenylmagensium 
bromide through a 1,4-nucleophilic addition on the pyridinyl ring in the presence of a 
catalytic amount of copper (I) iodide (5%) to give the carbamate 3 in 69% yield 
(Scheme 3.9.  The rationale for first treating ethyl nicotinate with ethyl chloroformate is 
to active the pyridinyl ring in order to make the nucleophilic addition easier. In addition, 
the presence of 5% copper iodide as a catalyst is required to exclusively produce 4-
phenylpiperindinyl as a product. Earlier attempts in the absence of this copper catalyst 
gave lower regioselectivity and 3 regioisomers, which are inseparable by 
chromatography, were produced. 
 
Scheme 3.9: 1,4-nuceophilic addition of the phenyl moiety to ethyl nicotinate activated 
by ethyl chloroformate 
 
 The next step in the synthesis involved putting a n-butyl group at the 2 
position of the dihydropyridine 3 through a 1,4-addition reaction with butylcuprate. 
Initially, due to the difficulties in the purification steps, since the by-product has the 
same retention as the desired product, only about 10 % of product was isolated from this 
reaction. Attempts to produce more yield of the product by varying the reaction 
conditions, reagents and catalysts were unsuccessful. Varying reaction conditions such 
as the reaction temperature from -80oC to room temperature resulted in more by-product 
instead.  Increasing the amount of cuprate (prepared either from copper (I) iodide or 
copper cyanide) used also did not help to increase the yield, but instead caused the 
deprotection of the ethyl carbamate protecting group to occur. Addition of Lewis acid 
led to immediate decomposition of the dihydropyridine 3.  Use of other organometallic 
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reagent such as organomagnesium, organozinc and also silanes, did not give any 
isolable yield of the desired product. Organomagnesium gave a mixture of the 1,2- and 
the 1,4- adducts as well as several by-product such as a deprotected compound.  Both 
organozinc and organosilane reagents did not give any reaction and only the starting 
material was recovered.  Lengthening the reaction time also did not help in producing 
the desired compound. Ethyl carbamate compounds are sensitive towards a series of 
nucleophile and can be cleaved readily by mild to strong nucleophilic agent to form an 
unstable unprotected 3,4-substituted dihydropyridine which may undergo air-oxidation 
to rearomatised and formed 3,4-disubstituted pyridine (Scheme 3.10).  
 
Scheme 3.10: Proposed reaction mechanism related to the deprotection of the 
dihydropyridine 4 and the rearomatisation. Nu = nucleophile, mainly from 
organometallic reagent 
 
 Since the substrate 3 is sensitive to organometallic reagent, the protecting group 
was changed from ethyl carbamate to t-butyl carbamate (t-BOC) in order to stabilise the 
compound under basic condition. Following the method of Hilgeroth and Baumiester 
(Higeroth and Baumeister, 2002) phenyl chloroformate was reacted with the nicotinate 
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ester 2 and subsequently subjected to treatment phenyl magnesium chloride in presence 
of CuI as catalyst (Scheme 3.11) to give the dihydropyridine 4 as the product. 
 
Scheme 3.11: 1,4-nuceophilic addition of the phenyl moiety to ethyl nicotinate 
activated by phenyl chloroformate 
 
 The substrate 2 was then transformed from phenyl carbamate to a BOC 
protected adduct by stirring with t-BuOK in THF at -42 oC.  BOC protecting group is 
acid labile but stable under basic condition as well as against nucleophilic attack when 
compared to the phenyl carbamate. Thus, the dihydropyridine 5 readily underwent 1,4-
addition reaction with cuprate prepared from copper (I) cyanide to give 31% yield 
(Scheme 3.12).  
 
 
Scheme 3.12: Functional group interconversion from phenyl carbamate to t-butyl 
carbamate followed by 1,4-Michael addition of butyl moiety insertion 
  
 In the subsequent step, the double bond from the piperidinyl ring was subjected 
to a reduction reaction.  Three different reagents were attempted, i.e., hydrogen gas with 
10 % palladium on activated carbon, HOAc with zinc dust, and sodium 
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cyanoborohydride with HCl.  Hydrogen gas with 10% palladium on activated carbon 
was found to be the most efficient of the three reducing agents where conversions using 
the hydrogen gas on palladium/carbon gave 99% yield. Reductions of 6 with sodium 
cyanoborohydride or zinc dust were rather inefficient and conversions were incomplete 
(Scheme 3.13).  
Scheme 3.13: Reduction of 6 using 10% palladium on activated carbon 
 
In summary, the first half of the synthesis pathway beginning from the nicotinic 
acid to adduct 7 hinges upon the workability of the second key step (i.e. Michael 1, 4-
addition reaction of the butyl chain) which required many attempts of various 
nucleophilic reagent, ranging from organocopper, organozinc, organomagnesium to 
silanes as well as the choice of Lewis acids that were all incompatibility with the ethyl 
carbamate group in the molecule. The low tolerance of the ethyl carbamate with low 
reactivity of the α, β-unsaturated ester to the Michael 1,4-addition reaction resulted in 
the revision of the choice of protecting group used in the step from ethyl carbamate to t-
butyl carbamate  (Scheme 3.14).  
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Scheme 3.14: Partial synthesis of designed ligand, with 3 moieties attached (1 to 7). 
Reagents and conditions: a: EtOH, H2SO4, reflux, 4h, then NH3(aq), 82%; b: EtOCOCl, 
-10oC, 30min, then PhMgCl, 5% CuI, THF, r.t., 2h, 69%; c: PhOCOCl, -10oC, 30min, 
then PhMgCl, THF, r.t., 2h, 62%; d: t-BuOK, THF, -42oC, 30 min, 72%; e: 
Bu2(CuCN)Li2, THF, -78oC, 31%, 6h; f: 10% Pd/C, H2, MeOH, r.t, 24h, 99%. 
 
 The next step in the synthesis involved a conversion of the ethyl ester to 
Weinreb amide.  Initially, a method reported by Williams and co-workers was 
employed, where the ester was reacted with NHMe(OMe) and an organomagnesium 
reagent, preferebly i-PrMgCl, to form Weinreb amide in one pot with low by-product 
and easy purification.  However, several attempts with the similar reaction conditions to 
make a Weinreb amide from ester 7 were unsuccessful. Varying the reaction 
temperatures did not make any changes and only the starting material was recovered. 
Presumably, the ester 7 is too hindered to be attacked by the nucleophile. Therefore, 
strategy was modified to make a carboxylic acid first, by hydrolysing the ester 7 with 
KOH, followed by general amide formation reaction. The ester 7 was easily hydrolysed 
with KOH under reflux to form carboxylic acid 8 in quantitative yield. The acid 8 was 
then subjected to a reaction with NHMe(OMe) with DMAP and PyBrOP as the 
carboxylic acid activator (Scheme 3.15) to form Weinreb amide 9 in 49% yield.  
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Scheme 3.15: Functional group interconversions from ethyl ester to Weinreb amide 
 
The Weinreb amide 9 was then subjected to insertion of the phenolic moiety, 4-
bromo-l,3-benzodioxole, via nucleophilic substitution to form a ketone. The 4-bromo-
l,3-benzodioxole was synthesised in 3 steps, starting from guaiacol following the 
method of Klix and co-workers (Klix et al., 1995).  Nahm and Weinreb reported that 
Weinreb amide would react cleanly with organometallic reagent to form ketone as a 
final product, where organomagnesium and organolithium are amongst the popular 
choices of organometallic used (Nahm and Weinreb, 1981).  However, in our hands, the 
Grignard reagent of the 4-bromo-l,3-benzodioxole did not work as expected. Varying 
the reaction temperature, reactant load (more equivalent of organometallic reagent) or 
replacing the organomagnesium with organolithium reagent was also unable to convert 
the amide 9 to the desired ketone 10 (scheme 3.16).  
 
Scheme 3.16: Reaction of Weinreb amide to make ketone by Grignard reagent 
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 The addition was only successful, albeit a very low yield of 10 at 8%, when the 
chelating agent TMEDA was added to the organomagnesium generated from 4-bromo-
l,3-benzodioxole with.  Due to the low efficancy of the conversion the Weinreb amide 
to the desired phenolic moiety, the synthesis route was revised to enable a better yield of 
product to be obtained.  The Weinreb amide 9 was converted to aldehyde 12 by LiAlH4 
in about 91% yield. The aldehyde 12 proved to be a better candidate for the conversion 
when it underwent the nucleophilic attack by the Grignard reagent generated from 4-
bromo-l,3-benzodioxole to make the secondary alcohol 13 in a more reasonable yield of 
58%. The racemic mixture of the alcohol 13 was then oxidised by Dess Martin 
periodinane to produce the ketone 10 in quantitative yield. With this alternative route, 
the same objective was achieved but with a better yield of 58% from the aldehyde 12   
to the ketone 10 although additional 2 steps were introduced. The final step in the 
synthesis involved the removal of two protecting group with BCl3, followed by the 
hydrolysis with methanol to furnish the targeted product 14 in 87% yield (Scheme 
3.17).  
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Scheme 3.17: Revised route from Weinreb amide 9 to furnish the targeted product 
 
 Since it has been demonstrated that the targeted product can be synthesised from 
aldehyde 12 in a relatively good yield, an alternative strategy is taken in order to further 
reduce the number of synthesis steps using the aldehyde 12 as one of the intermediate in 
the synthesis.  Aldehyde 12 was produced by first reducing the ester 7 to the alcohol 11 
with LiAlH4 in quantitative yield. This alcohol was then treated to DMP oxidation to 
produce the aldehyde 12 in 88 % yield (Scheme 3.18).  
 
Scheme 3.18: Revised route to synthesise aldehyde 12 from ester 7 
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The originally planned route that utilised Weinreb amide as a key intermediate 
gave only 3 % yield from ester 7 while the alternative route involving the aldehyde 12 
formed from Weinreb amide 11 as a key intermediate gave 27% yield from ester 7.  
Using the aldehyde 12 formed directly by reduction of the ester 7 as the key 
intermediate (without going through Weinreb amide 11) gave an even better yield of 
42% (from ester 7).  The three different routes of synthesis employed are illustrated in 
Scheme 3.19 and their related yields are summarised in Table 3.1. Considering the best 
route among the three, the overall yield starting from nicotinic acid to the targeted 
molecule was found to be about 4.7%. 
Scheme 3.19: Different routes to synthesise target molecule 14. Reagents and 
conditions: a: KOH, EtOH, reflux, 1h, 99%; b: NH Me(OMe).HCl, DMAP, PyBrOP, 
CH2Cl2, r.t., 19h, 49%; c: 4-bromo-l,3-benzodioxole, Mg, THF, TMEDA, r.t., 8%; d: 
LiAlH4, THF, -78 oC, 3h, quantitative of 11 and 91% of 12; e: DMP, CH2Cl2, r.t., 1h, 
88% yield from 11 to 12 and quatitative yield from 13 to 10; f: 4-bromo-l,3-
benzodioxole, Mg, THF, r.t., 3h, 58%; g: BCl3, CH2Cl2, -78 oC to r.t, 24h then MeOH, 
rt., overnight, 87%.  
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Table 3.2: Percent yield of the targeted product from 3 different route of synthesis 
Route No. of steps % yield (from 7) 
A: 7, 8, 9, 10, 14 4 3% 
B: 7, 8, 9, 12, 13, 10, 14 6 27% 
C: 7, 11, 12, 13, 10, 14 5 42% 
 
3.6.2 Stereochemical control of the proposed synthesis 
 
 Since no stereocontrol was exercised in the above synthesis, the products 
obtained are of a mixture of stereoisomers (enantiomer, diastereomer, etc.). However, 
only a pair of enantiomers of intermediates was observed throughout the synthesis, the 
exception being the secondary alcohol 13, where 2 pairs of enantiomers were obtained 
(Scheme 3.17).  This observation is corroborated by further examination of the Michael 
adduct 6 with the polarometric as well as the NOE NMR experiment.  
 
The polarograph indicated the compound 6 to show no significant reading in its 
optical rotation, indicating the compound 6 to be in the form of a racemic mixture. The 
relationship for the NOE NMR experiment performed on the compound 6 is as shown in 
Scheme 3.20(a). Irradiation of H-2 enhanced the signal for H-3 without enhancing H-4.  
This affirmed the assignment of the H-2 and H-3 to a cis-relationship while H-3 and H-
4 are in the trans-configuration. Irradiation of H-3 enhanced the signals for H-2, H-4 
and phenyl proton. Irradiation of H-4 enhanced the signals for H-3, H-5 and phenyl 
proton. The observed enhancement of the phenyl proton from irradiation of H-3, H-4 
and H-5 signals were further their position to be near the phenyl group. Irradiation of H-
5 enhanced the signals for H-4, H-6 and phenyl proton while irradiation of the H-6 
signal enhanced the signal for H-5 only. Through this series of NOE experiment, the 
relative configuration of the compound 6 was assigned as depicted in Scheme 3.20.  
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Scheme 3.20:  (a) The NOE correlation (showed in solid arrow) of the corresponding 
proton in compound 6. (b) Relative configuration of compound 6 assigned in two-
dimensional representation. 
 
(a) (b) 
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CHAPTER 4 
INHIBITION STUDY OF THE DESIGNED AND SYNTHESISED 
COMPOUND AGAINST DEN2 NS2B/NS3 SERINE PROTEASE 
 
4.1 Introduction  
 
The implementation of a therapeutic strategy by inhibiting proteases of HIV-1 
protease activity (Seife, 1997) has successfully generated a numbers of compounds 
(West and Fairlie, 1995) that inhibits HIV replication. By preventing the activity of the 
viral proteases that are responsible for producing structural and functional HIV proteins 
in host cells, HIV replication can be inhibited which may eventually halt the illness 
caused by HIV infection. In a similar manner, for the development of antiviral agent for 
DEN2 in this project, NS2B/NS3 serine protease was chosen to be the target enzyme 
since it is found to be important for proteolytic cleavage activity in the host cells.  
 
Earlier work has shown some natural products inhibit the activities of the 
NS2B/NS3 DEN2 protease in a competitive manner with the peptide substrate 
Boc-Gly-Arg-Arg-4-methylcoumaryl-7-amide (Tan et al., 2006).  These natural 
products were then used as templates to design a novel compound which is anticipated 
to possess inhibitory activities against DV. This chapter discusses the evaluation of the 
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synthesised compound (named CP14) in its ability to inhibit the DEN2 NS2B/NS3 
serine protease activity and the validation of the model used in designing the inhibitor.  
For this purpose, CP14 was initially evaluated on the DENV-infected HepG2 cells. 
Inhibition or reduction the cell cytopathic effect (CPE) exhibited by the DENV-infected 
HepG2 cells indicated the efficacy of the compound to inhibit the viral activity. Kinetic 
assay of CP14 was then performed on the DEN2 NS2B/NS3 serine protease 
recombinant in accordance to the work reported by Yusof and co-workers (Yusof et al., 
2000). Finally, RT-PCR experiment was then carried out to investigate the effect of 
CP14 against the replication process of DEN2 NS2B/NS3 serine protease.  
 
4.2 Cell Cytopathic Effect 
 
A viral infection especially dengue virus infection can be identified by 
examining the cytopathic effect (CPE) exhibited by the virus-treated cell culture. Cell 
cytopathic effect refers to morphological changes in cells, especially in tissue culture. 
These morphological changes are usually associated with the viral replication that 
invade and destroy the cell lines. When the infection is performed in tissue cultures, the 
virus spread is constrained by an overlay of the nutrient medium and the cytopathic 
effect is visualised as viral plaques. A study has to be carried out first to determine the 
possibility of a virus infection onto the tissue culture of interest, since not all types of 
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viruses are able to present the CPE on the tissue culture.  
 
In the case of DENV infection, CPE on various cell lines has been carried out as 
early as 1961 when Buckley reported the observed CPE on the DENV-treated HeLa cell 
line (Buckley, 1961). Other cell lines, such as larval tissue (C6/36) (Corner and Ng, 
1987), kidney cells (BHK) (Cleaves, 1985) and human liver cells were reported 
elsewhere. In this work, CP14 was evaluated on the human hepatoma cells (HepG2) for 
its ability to inhibit CPE. HepG2 cells were used in this study since it has been reported 
that liver injury is found to be persistent in DF and DHF patients (Phoolcharoen and 
Smith, 2004). 
 
4.3 Analysis of Enzyme Kinetics Data 
 
Enzyme kinetics is the study of the rate of chemical reaction catalysed by 
enzymes. For a simple, single substrate and irreversible reaction, Michaelis-Menten 
equation (see equation 1) is commonly used to describe the relationship between the 
rates of substrate conversion by an enzyme and the concentration of the substrate as 
shown in equation (2). 
max
m
V [S]
v
K  + [S]   

                                                          (1)         
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where [E], [S], [ES] and [P] represent the concentration of enzyme, substrate, 
enzyme-substrate complex and product, respectively. The Lineweaver–Burk plot is 
widely used to determine important terms in enzyme kinetics, such as Km and Vmax.   
A graphical representation of the Michaelis-Menten equation gives a quick, visual 
impression of the different forms of enzyme inhibition; i.e., either as competitive, 
non-competitive or uncompetitive inhibition. These inhibitions are reversible inhibitions 
which involve non-covalent interactions such as hydrogen bonds, hydrophobic 
interactions and ionic bonds between the inhibitor and the enzyme.  
 
The Lineweaver-Burk plot, also termed double reciprocal plot, uses the modified 
Michaelis-Menten equation. Rearrangement of equation (1) through inversion and 
factorisation produced a straight line equation used in the Lineweaver-Burk plot as 
follows: 
  
m
m a x m a x
K1 1 1
v V [ S ] V
 
  
 
                                                (3) 
 
A plot of 1/v versus 1/[S] gives a straight line whose y-intercept is 1/Vmax and 
the slope is Km/Vmax. Substitution of 1/v with zero gives the x-intercept (ie., 1/[S]) as 
−1/Km  (Figure 4.1).  The Km and Vmax values can then be obtained through the y- and 
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x-intercept by plotting the reaction velocity at different substrate concentration.  The 
Km and Vmax values are used to evaluate the type of inhibition exhibited by the 
inhibitors against the enzyme of interest, when the assays are performed in the set of 
different inhibitor concentration.  
 
Figure 4.1: Lineweaver-Burk plot of 1/v versus 1/[S] to evaluate Km and Vmax (Murray 
et al., 2003) 
 
4.3 Competitive, non-Competitive and Uncompetitive inhibition: A Different 
Reversible Enzyme Inhibition Overview 
 
Generally, the reversible enzyme inhibition can be classified into three different 
inhibition modes: competitive, non-competitive and uncompetitive inhibition. In terms 
of their mode of action, a competitive inhibitor competes with the enzyme’s substrate to 
enter the active site or the binding site of the enzyme. A non-competitive inhibitor may 
bind at a site other than the active site of the enzyme (or termed as allosteric site) 
without affecting the substrate’s binding, where the formation of enzyme-inhibitor, or 
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enzyme-substrate, or enzyme-substrate-inhibitor complexes are all possible. 
Conversions of the substrate to the product by the enzyme inhibited by non-competitive 
inhibitors are still possible but usually at a reduced efficacy. Uncompetitive inhibition is 
exhibited by the inhibitor that binds to an enzyme-substrate complex to form 
enzyme-substrate-inhibitor complex and prevent the enzyme from converting the 
substrate to a product. A truly uncompetitive inhibitor is said to bind exclusively to the 
enzyme-substrate complex and have no affinity for its related free enzyme. 
 
While the maximum velocity of the enzyme (Vmax) and the Michaelis constant, 
(Km) are compared among the studies of competitive, non-competitive and 
uncompetitive inhibitor that present in the enzyme respectively, with the different 
concentration of inhibitor, [I] screened over a series of substrate concentration, their 
difference are readily be distinguished by a serial of reciprocal plot of 1/v versus 1/[S] 
(or termed as Lineweaver-Burk plot) (Figure 4.2).  The Table 4.1 below summarises 
the different properties exhibited by the inhibitors.   
 
Table 4.1: Comparison of the binding site, Vmax and Km among different type of 
inhibitor 
Type of Inhibitor Competitive Non-Competitive Uncompetitive 
Binding site Active sites Allosteric sites Allosteric sites 
Vmax Unchanged Reduced Reduced 
Km Increased Unchanged Increased 
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Figure 4.2: Lineweaver-Burk plot of different inhibitor. A: competitive; B: 
non-competitive; C: uncompetitive 
 
Thus, analysis of enzyme kinetics of a key enzyme would provide insight into 
the viral activities such as replication and give important information which can help in 
drug design research. 
 
A 
B C 
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4.4 Materials and methods 
4.4.1 Materials 
 
Ni2+ -nitrilotriacetic acid (NTA)-agarose resin was from Qiagen (Chadowrth, 
CA). Fluorogenic peptide subtrate Boc-Gly-Arg-Arg-MCA was obtained from Peptide 
Institute, Inc (Osaka, Japan). Amersham Pharmacia supplied the Sephadex G-75 for 
column separation. AMC (7-amino-4-methylcourmarin) was purchased from Sigma-
Aldrich. 
  
4.4.2 Instrument used for Analysis and Bioassay  
 
The intensity of the fluorogenic moiety (7-amino-4-methylcourmarin, AMC) 
from the cleaved fluorogenic peptide substrate was measured at excitation 385 nm and 
emission 465 nm using Cary Eclipse Varian fluorescent spectrophotometer. Shimadzu 
UV-Visible Recorder Spectrophotometer (UV-160) was used for OD and quantitative 
protein assay.  
 
4.4.3 Expression and Purification of DEN2 NS2B/NS3 serine protease complex 
 
The protein precursor consist of N-terminal six histidine tag that fused 
sequentially to 40-residue NS2B cofactor, a linker of 10 residues and the first 185 
amino acids of NS3 was expressed using transformed competent Escherichia coli strain 
XL1-Blue MRF; then harvested, purified and refolded by employing the established 
procedures (Murthy et al., 1999; Yusof et al., 2000) to synthesise proteolytically active 
protease complex, DEN-2 NS2B/NS3pro. Twelve litres of competent Escherichia coli 
strain XL1-Blue MRF was cultured in LB medium in the presence of ampicillin 
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(100µg/ml) at 37oC until O.D. 600 nm reached approximately 0.6. Isopropyl-β-D-
thiogalactoside (IPTG) was used to induce the overproduce of protease for 2 hours, 
collected by centrifugation, and stored at -70 °C until used. After resuspension in buffer 
A (100 mM Tris-HCl, pH 7.5, 300 mM NaCl), the cell lysis was performed using 
lysozyme (1mg/ml) on ice for 30 min, followed by centrifugation and pellet 
resuspension for 1 h at 4 °C in buffer B (100 mM Tris-HCl, pH 8.0, 300 mM NaCl, 6 M 
urea). The suspension was later undergoes sonication on ice using a cell distruptor. The 
denatured lysate was kept on ice for 1 h and clarified by centrifugation for 1 h at 4 °C. 
To purify the protein of interest, the NS2B/NS3pro was isolated using a Ni2+-NTA 
affinity column and subsequently purified using Sephadex G-75 gel filtration column. 
The ammonium sulfate precipitated proteins were then refolded by successive dialysis 
to yield the active NS2B/NS3pro that was then stored at -70oC until used. 12 % SDS-
polyacrylamide gel electrophoresis (PAGE) was used to trace the protease-containing 
fractions both after Ni2+-NTA and Sephadex G-75 gel filtration, and determine the 
purity of the enzyme after re-naturing by dialysis. Protein concentration was determined 
by UV-visible spectrometer using bovine albumin standards and Bradford reagent. 
Figure 4.3 surmised the scheme of harvesting and purification of DEN2 NS2B/NS3 
serine protease complex. 
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Figure 4.3: Workflow of harvesting and purification of DEN2 NS2B/NS3 serine 
protease complex. Buffer A: 100 mM Tris-HCl, pH 8.0/300 mM NaCl; Buffer B: 100 
mM Tris-HCl, pH 8.0/300 mM NaCl, 6M urea; Buffer C: 100 mM Tris-HCl, pH 
7.5/300 mM NaCl, 6M urea; Buffer D: 100 mM Tris-HCl, pH 7.5/300 mM NaCl 
 
 
 
 
Culture of E. coli XL1-Blue MRF overnight in incubator with 
100 µg/ml ampicillin and vigorous shaking 
Addition of 0.5 mM IPTG at optical density (600nm) 0.6 of 
culture to enhance expression 
Centrifugation to collect pellet (after 3 hours) 
Re-suspension in buffer A, lysis by lyzozyme (1mg/ml) on ice for 
30 min, centrifugation and pellet re-suspended in buffer B 
Sonification (9x 10 sec) on ice, Incubation, Centrifugation 
Ni2+ affinity chromatography of supernatant, SDS PAGE 
Sephadex G-75 gel filtration chromatography of 2nd and 3rd peak 
fractions; absorbance of fractions at 280 nm and SDS PAGE 
 
Dialysis of pooled 5th – 13rd fractions against three changes of 
buffer D; centrifugation 
Ammonium sulfate precipitation (70% saturation), re-centrifugation 
Re-suspension of pellet in buffer D; stored at -70 oC until use for bioassay 
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4.4.4 DEN2 NS2B/NS3 Inhibition assay using fluorogenic peptides  
 
Methods employed for DEN2 NS2B/NS3 inhibition assay was similar to the one 
that established by Yusof et al., (2000). The protease assay was performed in 96-well 
microtiter plates with a Cary Eclipse Varian Fluorescent Spectrophotometer at an 
excitation wavelength of 355 nm and emission wavelength of 460 nm at 37 °C. The 
standard reaction mixtures (200 µl) contained 200 mM Tris-HCl, pH 8.5, and 
fluorogenic peptide substrate. Preliminary studies were done to establish and the rate of 
product (7-amino-4-methyl-coumarin or AMC) released into the supernatant solution 
was determined fluorometrically [l (excitation) =385 nm, l (emission) =465 nm]. The 
substrate used was Boc-Gly-Arg-Arg-4-methylcoumaryl-7-amide (MCA). Stock 
solutions of substrate (100 mM) were prepared by dissolving the peptides in dimethyl 
sulfoxide, followed by dilution in water to 1 mM working stock before use. Substrate 
concentration was then varied between 25 and 250 µM, and signals were converted to 
concentrations by comparison with standard amounts of free AMC (Sigma). After 
enzyme addition, the reaction mixtures were incubated for 30 min at 37oC and the 
reaction was terminated with 1.9 ml of 125 mM ZnSO4 (Brenner et al., 1992). The 
supernatant was then subjected to micro-centrifugation for 1 min at 15 000 rpm to 
remove the precipitate. The rate of the fluorogenic fragment (AMC) released from the 
substrate used was fluorometrically determined [l (excitation) = 385 nm, l (emission) = 
465 nm] and monitored continuously over a period of 30 min. The kinetic parameters 
were calculated from non-linear regression. 
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4.4.5 Determination of Ki for the synthesised compound 
 
The inhibition constant, Ki, of the synthesised compounds were determined 
essentially the same way as in DEN-2 protease inhibition kinetic assays by varying the 
concentrations of substrate and inhibitors. The standard 100 µL reaction mixtures 
contained 2 µM DEN2 protease complex and Tris-HCl buffer of concentration 200 mM 
at pH 8.5. Four different concentrations of the synthesised compound, varying from 0 – 
400 µM were used for the assays. For each concentration of inhibitor tested, the 
fluorogenic peptide substrate Boc-Gly-Arg-Arg-MCA concentrations were varied from 
0 - 100 µM. The readings were taken in triplicates.  
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4.5 Results 
4.5.1  Cytopathic effect study of the compound 14  
 
In vitro cell-based study on the cytopathic effect of the compound 14 (termed 
“CP14”) was carried out at the Department of Molecular Medicine, Faculty of 
Medicine, University of Malaya.  Biological activity studies were initially carried out on 
cell culture system to determine the response of CP14 to virus-host interaction.  Human 
hepatoma cells (HepG2) were used as host cells in this study for the reason mentioned 
previously (see Chapter 4, section 4.2). In addition, participation of the dengue virus 
was also exhibited in the HepG2 cells since the intracellular DEN virus particles were 
found from the intracytoplasmic vesicles of the infected HepG2 cells (Marianneau et 
al., 1998)  
 
The liver infection was identified by the cytophatic effect (CPE) on the infected 
HepG2 cell, where changes in the liver cell morphology were observed.  An increment 
of the cell size (hyperthrophy) or necrosis that is presented as clear and opaque circles 
was observed under electron micrograph of the infected HepG2 cell as shown in Figure 
4.4.   
 
Figure 4.4: HepG2 cell morphology. A: normal cell; B: cell infected with DEN2 virus 
and shown CPE. 
 
A B 
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Prior to the biological screening, a cytotoxicity profile of the compound towards 
the HepG2 cells was established to prevent overdose effect that would kill the cells.  
The maximum non-toxic dose (MNTD) of CP14 was determined and found to be as 
high as 25 μg/ml.  Thus, the screening for CPE on the cells was performed with CP14 at 
the concentration of 25 μg/ml or lower.  Different virus titres were used (10, 100 and 
1000 TCID50/ml) for the screening.   At the highest virus titre of 1000 TCID50/ml, no 
CPE was observed on the infected HepG2 cells when 10μg/ml of CP14 was used. This 
indicates the ability of CP14 to protect the cells from DENV2 infection.  In addition, 
cell-based screening assay (Figure 4.5) showed the highest inhibitory activity at this 
concentration to be 80% inhibition for the virus titre of 1000 TCID50/ml.  This 
observation suggested effective inhibition by CP14 at a concentration of lower than that 
of the MNTD value.   
 
 
Figure 4.5: Percent inhibition of CP14 on various DEN2 virus titres in HepG2 cells 
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4.5.2  In vitro kinetic assay of CP14  
 
The kinetic assay of the DEN2 NS2B/NS3 was carried out in the Department of 
Molecular Medicine, Faculty of Medicine, University of Malaya.  Prior to enzyme 
inhibition assay on CP14, the enzyme concentrations as well as substrate concentrations 
were optimised.  A standard plot of intensity as a response to the concentration of 
fluorogenic moiety of the peptide substrate, AMC (7-amino-4-methylcoumarin), was 
obtained (Figure 4.6) for the conversion of intensity to the concentration to be carried 
out and the enzyme velocity to be calculated. The compound was diluted into three 
different concentrations in a range of substrate concentrations.  
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Figure 4.6: Plot of intensity versus concentration of fluorogenic moiety of the peptide 
substrate, AMC 
 
At the optimum protease concentration, the inhibition assays were performed in 
several series of substrate concentration, [S], from 25 mM to 150 mM. As a control, a 
series of [S] with no compound was added to the enzyme. CP14 with the concentration 
of 70.7 mM to 176.8 mM to 353.7 mM were added into these series of [S], resulting 4 
different curves of enzyme velocity versus [S] plotted. The respective regressions (R
2
) 
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of the curve fitting were exhibited to be more than 0.96, indicating the reasonable curve 
fittings were presented (Figure 4.7).  
 
Generally, reduction of the enzyme velocity as well as the Vmax with CP14 
present in the system resembled the inhibition effect exhibited by the CP14.  However, 
while the curve of no inhibitor and the concentration of CP14, [I] = 70.7 mM, 176.8 mM 
gave a hyperbolic curve, the plot for [I] = 353.7 mM gave a sigmoidal curve. The 
deviation of the plot from a normal hyperbolic curve to a sigmoidal curve could be 
attributed by the elevated concentration of the inhibitor, [I] that could cause an early 
saturation of the inhibited enzymatic activity. However, the incremental concentration 
of the substrate, [S] under the saturated condition caused the prevalence of the 
alternative enzymatic mechanism. The data sets were then analysed further by plotting a 
Lineweaver-Burk plot. 
Velocity vs. Substrate Concentration
R
2
 = 0.9975
R
2
 = 0.9695
R
2
 = 0.9823
R
2
 = 0.9743
-0.05
0
0.05
0.1
0.15
0.2
0.25
0.3
0.35
0.4
0.45
0 20 40 60 80 100 120 140 160
Substrate Concentration (mM)
V
e
lo
c
it
y
 (
m
M
m
in
-1
) No Inhibitor
[I]=70.7 uM
[I]=176.8 uM
[I]=353.7 uM
 
Figure 4.7: Curves with different concentration of CP14, [I], of enzyme velocity versus 
substrate concentrations 
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4.5.3 Lineweaver-Burk plot of the inhibition assays  
 
The study of the mode of inhibition for CP14 was carried out by fitting the 
kinetic data to the Lineweaver-Burk plot (Figure 4.8).  The control data (no inhibitor 
added) gave a gradient of the slope at 347.73 min
-1
.   Increasing the concentration of 
CP14 from 70.7 mM to 176.8 mM to 353.7 mM resulted in the increase in the gradient of 
the slope (Figure 4.8).  This reflects the increase in inhibitory activity with increasing 
concentration of CP14. The series of [I] = 70.7 mM and [I] =176.8 mM resembles the 
non-competitive behaviour, when these lines were intersected close to the x-axis. 
 
However, the plot obtained at [I] = 353.7 mM did not show the same trend as 
that of the two with the lower inhibitor concentration. Presumably, the mode of 
inhibition of the inhibitor may have changed from a non-competitive one to another 
mode of inhibition. As mentioned earlier, the high concentration of [I] may caused early 
saturation and alteration in the mode of inhibition observed when the [S] was increased.  
Figure 4.8: Lineweaver-Burk plot of CP14 with the different concentration of inhibitor. 
no inhibitor, : [I] = 70.7 mM, ▲: [I] = 176.8 mM, : [I] = 353.7 mM 
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4.5.4  Effect of CP14 against DEN2 Viral Replication 
 
To investigate further the inhibition mechanism of CP14 against the viral 
replication in the HepG2 cell lines, Reverse Transcriptase-Polymerase Chain Reaction 
(RT-PCR) experiments were carried out.  RT-PCR is use to detect and quantify a 
specific sequence in a DNA sample as absolute number of copies or relative amount 
when normalized to DNA input or additional normalizing genes.  The RT-PCR 
experiments were carried out in the Department of Molecular Medicine, University of 
Malaya (Mudiana, 2010) to ascertain the numbers of gene copies of the DENV2 when 
exposed to CP14. 
 
 
Figure 4.9: RT-PCR of DENV2 serine protease from HepG2 cell in the presence of 
CP14 (source: Mudiana Thesis, 2010, taken with permission) 
 
The profile generated for CP14 (Figure 4.9) indicated no apparent changes in the 
DENV2 protease gene copies.  This is seen from 820 bp band which neither decreased 
nor increased in its intensity as compared to the positive control of DENV2.  It is 
therefore concluded that CP14 has no influence on the DENV2 protease gene 
expression and was not affecting the viral replication process.  
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4.6 Discussions 
 
The compound, CP14 was designed based on a template generated from two 
natural products and a synthesised small ester molecule which have shown competitive 
inhibition towards the NS2B/NS3 serine protease activities. To validate the ligand 
design, CP14 was initially bioassayed with the DENV2-infected HepG2 cell lines. The 
results exhibited a good CPE inhibition by CP14. At 10 mg/ml of CP14, which was way 
below its MNTD (25 mg/ml), high percent inhibition was exhibited (80%) at the highest 
virus titre (1000 TCID) used. This result warranted a further investigation on the 
inhibition mechanism exhibited by CP14. The kinetic assays were therefore carried out 
to examine the effect of CP14 against the DEN2 NS2B/NS3 serine protease. 
 
When the CP14 was screened on the NS2B/NS3 serine protease recombinant, 
the Lineweaver-Burk plot analysis exhibited a non-competitive-like inhibition 
behaviour at two lower concentration series ([I] = 70.7 mM and 176.8 mM). However, 
while the plot of velocity versus [S] gave hyperbolic curves for [I] = 70.7 mM and 176.8 
mM, doubling the [I] from 176.8 mM to 353.7 mM seemed to make the enzyme behave 
differently, i.e., with [I] =353.7 mM, a hyperbolic curve and the sigmoidal curve was 
observed. Thus, the mode of inhibition exhibited by CP14 could not be confirmed and 
further investigation is required. 
 
For the RT-PCR experiments, non-apparent changes of the intensity of the 
NS2B/NS3 gene copies observed when CP14 was introduced to the DENV2-infected 
HepG2 cells (Figure 4.9). This observation was indicated that CP14 has no significant 
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effect on the viral replication process. However, since inhibition of CPE of the infected 
HepG2 cells was observed, it can be concluded that CP14 is still inhibiting the virulence 
of DENV2.  
 
The design of CP14 was performed based on the site where the natural products, 
(panduratin A and 4-hydroxypanduratin A), were observed to bind in silico, to the 
binding site, presumably the active site of the enzyme. These natural products exhibited 
competitive inhibition in the protease assay (Tan et al. 2006).  However, the bioassay 
results of CP14 did not clearly reflect the expected inhibition mode.  Although in 
theory, CP14 showed good binding to the active site in silico (docked energy = -11.4 
kcal/mol), it may not even reach the binding site of the protein experimentally to 
participate in competitive inhibition. To address this issue, a blind docking (Hetényi and 
van der Spoel, 2002) was performed between the whole DEN2 NS2B/NS3 serine 
protease and CP14 to locate other plausible ligand binding sites using 
AUTODOCK3.05 software package (Morris et al., 2001).  
 
The blind docking results revealed 4 binding pockets including the active sites 
(Figure 4.10). From a hundred runs of blind docking on the whole NS2B/NS3 serine 
protease, about 65% of the molecule CP14 populated at the active site. However, 35% 
of CP14 docked at sites other than the active sites which could be alternative binding 
sites for CP14. The difference of the mean docked energy for these two top docked 
clusters was only 0.46 kcal/mol.  This suggested that there could be other possible 
binding sites that may bind CP14 readily, and consequently the possibility of other 
mode of action by CP14.    
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Figure 4.10: Plausible bindings suggested by AUTODOCK3.05. A, B, C, D represents 
4 different sites of binding, where A is the enzyme active sites. The binding ligands of 
CP14 were superimposed and displayed as CPK. 
 
CP14 used for the assay were racemic since no chiral resolution was carried out 
on the mixture prior to the screening.  Although not very likely, this could cause some 
variation in the inhibitory pattern observed since the pair of enantiomers may have 
different effect from each other on the enzyme and could alter the profile of action of 
the enzyme.   
 
A 
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D 
His51 
Asp75 
Ser135 
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CHAPTER 5 
GENERAL DISCUSSION 
 
 Dengue is now an emerging disease, particularly in tropical countries. While the 
effective medications or vaccines still remain unavailable, many efforts are made to find 
the best therapeutics for this disease.  
 
Competitive inhibition against DEN2 NS2B/NS3 serine protease was observed 
by 4-hydroxypanduratin A and panduratin A that were purified from the rhizome extract 
of Boesenbergia rotunda (Tan et al., 2006). Using this information, the SBDD work 
was employed to design a new class of drug candidate. This work began with the 
construction of the protein model of dengue virus serine protease, NS2B/NS3 using 
homology modelling techniques. The sequence alignment and protein folding of the 
DEN2 NS2B/NS3 serine protease were built based on the protein crystal template of 
HCV NS3/NS4A (Kim et al., 1996), where this technique (Brinkworth et al., 1999) was 
revisited with more analyses and comparisons. Although the NS3 protein were 
successfully crystallised (Murthy et al. 1999), the absence of the NS2B as the protease 
co-factor within the crystal has caused some uncertainty for it to be the appropriate 
model to work on, since this serine protease requires NS2B to bind in as the co-factor 
for a more effective proteolytic activity. NS3 without NS2B exhibited comparatively 
lower proteolytic activity by more than 3000 fold (Yusof et al., 2000). In addition, the 
better reading of VERIFY3D (90.4) and ERRAT (77.1) gave better score on the 
structural verification of the homology model NS2B/NS3 serine protease which may 
implicate a better protein structure compared to DEN2 NS3 crystal structure.  
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 The homology model was then used to study the binding interactions between 
the protein and the competitive inhibitors. To do this, protein-ligand docking was 
performed using AUTODOCK 3.05 as the molecular docking tools. 4-
hydroxypanduratin A, panduratin A and ethyl 3-(4-(hydroxymethyl)-2-methoxy-5-
nitrophenoxy)propanoate were used as the ligands. The docking studies were focused on 
the catalytic triad of the protein, and these bound ligands were observed to exhibit 
hydrogen bonding with the residues Ser-135 and Gly-151; Van der Waals interactions 
with Ser-131, Pro-132, Tyr-150 and Asn-152; and hydrophobic interactions in the 
hydrophobic pocket comprising Leu-128, Pro-132 and Val-155. The hydrogen bonding 
observation may implicate the involvement of these residues to the oxanion hole 
formation, which was found to be different from previously reported observations 
(Murthy et al., 1999). The lack of the additional  interaction as well as the 
additional hydrophobic interactions with Val-52 could result in the lower inhibitory 
activity exhibited by ester 3, as compared to panduratin A and 4-hydroxypanduratin A.  
 
 A new ligand was designed based on the template for interactions obtained 
between the natural products and the protease. This newly designed ligand is hoped to 
exhibit the similar binding interaction or maybe even better binding affinity for the 
DEN2 NS2B/NS3 serine protease.  For the design, the phenol moiety found in the 
panduratin A was kept constant but the position of the hydroxyl group was readjusted to 
give better binding possibility. In addition, it was observed in previous study (Yusof et 
al., 2000) that the DEN2 NS2B/NS3 serine protease recognises a dibasic site for 
cleavage. Based on this observation and to explore new chemical space, a piperidine 
functionality was included into the design of this new ligand. Docking of this newly 
designed ligand showed a better docked energy at -11.4 kcal/mol compared to 4-
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hydroxpanduratin A (-10.2 kcal/mol) and panduratin A (-10.1 kcal/mol). This opened an 
opportunity of new drug candidate for antiviral activity for dengue virus serine protease. 
 
A convergent synthesis plan that connects four different moieties was then 
adopted in the system of the newly designed ligand. This involved the synthetic strategy 
of dihydropyridine synthesis, 1,4-Michael addition and Weinreb ketone synthesis. The 
synthesis was carried out using nicotinic acid as the starting material. The newly 
designed compound, 1(benzo[1,3]dioxol-4-yl)(2-butyl-4-phenylpiperidin-3-yl) 
methanone (or CP14 in the chapter 4), was obtained in 10 step in about 4.7% overall 
yield. Although the synthesis attempted above was not a asymmetric strategy, it has 
exhibited some kind of stereocontrol, particularly during the Michael addition reaction. 
This is then give some insights into the strategy which could be used for a 
stereocontrolled synthesis in future work. 
 
 Preliminary biological studies to evaluate the effectiveness of this newly 
designed ligand on DEN2 virus activities were carried out in the Department of 
Molecular Medicine, University of Malaya. On the DEN2 virus infected HepG2 cells, 
about 80% inhibition of the CPE was exhibited by this ligand at 10 g/ml, where it was 
below the MNTD of 25 g/ml. Since the design of the new ligand was focused on the 
active site of the protease, it is expected to exhibit competitive inhibitory activities 
similar to its mould (panduratin A and 4-hydroxypanduratin A). However, this 
compound did not show competitive inhibition when tested against the protease assay. 
Although the compound showed, in theory, good binding to the DEN2 NS2B/NS3 
serine protease, experimentally, it may not bind to the active site as expected. Thus, 
although inhibitory activity was observed, it may not be competitive in nature. RT-PCR 
experiment indicated that the ligand has little or no influence on the DENV2 serine 
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protease gene expression, and thus it was not affecting the viral replication. Blind 
docking of the newly designed ligand showed about 65% probability of the ligand 
docked to the active site. About 35% probability indicated ligand to be docked at other 
site of the protease. This result seems to support possibility of other binding site for the 
newly designed ligand which could explain the lack of competitive nature of the ligand. 
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CHAPTER 6 
CONCLUSIONS 
 
In an effort to generate new drug candidates as therapeutic agents against dengue 
disease, structural-based drug design, synthesis and biological evaluation approaches 
were employed in this work. In the absence of a protein crystal structure, a homology 
model of DEN2 NS2B/NS3 serine protease was built. The protein structure was verified 
under PROCHECK, VERIFY 3D and ERRAT.  
 
Docking of ligands were performed using the existing competitive inhibitors 
(panduratin A, 4-hyroxypanduratin A and ethyl 3-(4-(hydroxymethyl)-2-methoxy-5-
nitrophenoxy)propanoate to study the ligand binding interactions that contribute to 
enzyme inhibition activity. 
 
Based on the binding interaction study, this ligand was then synthesised starting 
from nicotinic acid in 10 steps. Bioassay study a protease assay of the synthesised 
ligand, however, did not show competitive inhibition for the catalytic site of the 
NS2B/NS3 serine protease. 
